



Clinical trial results:

Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT)

Summary

EudraCT number	2004-003635-31
Trial protocol	AT BE GB CZ IT DE ES SE HU PT
Global end of trial date	18 November 2015

Results information

Result version number	v1 (current)
This version publication date	18 June 2016
First version publication date	18 June 2016

Trial information

Trial identification

Sponsor protocol code	IM103-008
-----------------------	-----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00256750
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussee de la Hulpe 185, Brussels, Belgium, 1170
Public contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, clinical.trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, clinical.trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 November 2015
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	18 November 2015
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial was to evaluate the effect of belatacept to provide protection from organ rejection following kidney transplantation while avoiding some of the toxic effects of standard immunosuppressive medications such as kidney damage. Effects on kidney function and subject survival as well as drug safety were also studied.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial subjects were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	13 January 2006
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	24 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 51
Country: Number of subjects enrolled	Austria: 8
Country: Number of subjects enrolled	Australia: 28
Country: Number of subjects enrolled	Belgium: 11
Country: Number of subjects enrolled	Brazil: 60
Country: Number of subjects enrolled	Canada: 35
Country: Number of subjects enrolled	Czech Republic: 6
Country: Number of subjects enrolled	France: 90
Country: Number of subjects enrolled	Germany: 4
Country: Number of subjects enrolled	Hungary: 2
Country: Number of subjects enrolled	India: 98
Country: Number of subjects enrolled	Israel: 3
Country: Number of subjects enrolled	Italy: 16
Country: Number of subjects enrolled	Mexico: 99
Country: Number of subjects enrolled	Poland: 6
Country: Number of subjects enrolled	South Africa: 6
Country: Number of subjects enrolled	Spain: 19

Country: Number of subjects enrolled	Sweden: 5
Country: Number of subjects enrolled	Switzerland: 3
Country: Number of subjects enrolled	Turkey: 2
Country: Number of subjects enrolled	United States: 186
Worldwide total number of subjects	738
EEA total number of subjects	167

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	1
Adults (18-64 years)	694
From 65 to 84 years	43
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was conducted at 34 centers in 21 countries.

Pre-assignment

Screening details:

738 subjects enrolled, 686 subjects randomized. Reasons for non-randomization include 5 subjects withdrew consent, 1 subject lost to follow-up, 34 subjects no longer met study criteria, and 12 subjects for other non-listed reasons. 20 not transplanted; 10, 4, 6 in the CsA, Belatacept LI, Belatacept MI, respectively.

Period 1

Period 1 title	Transplanted Pre-Treatment
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Cyclosporine

Arm description:

Cyclosporine (CsA): tablet, oral

1st month target: 150-300 nanogram/meter (ng/m)

After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)

Arm type	Active comparator
Investigational medicinal product name	Cyclosporine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received cyclosporine 150-300 ng/mL and 100-250 ng/mL at Month 1 and after Month 1, respectively.

Arm title	Belatacept LI
------------------	---------------

Arm description:

Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Arm title	Belatacept MI
------------------	---------------

Arm description:

Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every

4 weeks, q 4 weeks, 24 months (LT)

Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Number of subjects in period 1^[1]	Cyclosporine	Belatacept LI	Belatacept MI
Started	221	226	219
Completed	215	226	219
Not completed	6	0	0
Adverse event, serious fatal	1	-	-
Consent withdrawn by subject	3	-	-
Not specified	2	-	-

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: The number of subjects reported in the baseline period are different from the worldwide number enrolled in the trial, as out of 738 subjects enrolled only 666 were transplanted, rest 52 subjects were not randomised and 20 were not transplanted.

Period 2

Period 2 title	Post-Transplant Treated (12 months)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Cyclosporine

Arm description:

Cyclosporine (CsA): tablet, oral

1st month target: 150-300 nanogram/meter (ng/m)

After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)

Arm type	Active comparator
Investigational medicinal product name	Cyclosporine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received cyclosporine 150-300 ng/mL and 100-250 ng/mL at Month 1 and after Month 1, respectively.

Arm title	Belatacept LI
Arm description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Arm title	Belatacept MI
Arm description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Number of subjects in period 2	Cyclosporine	Belatacept LI	Belatacept MI
Started	215	226	219
Completed	174	183	173
Not completed	41	43	46
Adverse event, serious fatal	3	2	4
Consent withdrawn by subject	-	3	5
Adverse event, non-fatal	20	12	8
Not specified	5	4	2
Lost to follow-up	1	-	-
Protocol deviation	2	-	-
Lack of efficacy	10	22	27

Period 3

Period 3 title	Post-Transplant Treated (24 months)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Cyclosporine
------------------	--------------

Arm description:

Cyclosporine (CsA): tablet, oral

1st month target: 150-300 nanogram/meter (ng/m)

After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)

Arm type	Active comparator
Investigational medicinal product name	Cyclosporine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received cyclosporine 150-300 ng/mL and 100-250 ng/mL at Month 1 and after Month 1, respectively.

Arm title	Belatacept LI
------------------	---------------

Arm description:

Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Arm title	Belatacept MI
------------------	---------------

Arm description:

Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Number of subjects in period 3	Cyclosporine	Belatacept LI	Belatacept MI
Started	174	183	173
Completed	153	176	164
Not completed	21	7	9
Adverse event, serious fatal	3	-	-
Consent withdrawn by subject	5	1	-
Adverse event, non-fatal	7	3	6
Not specified	2	-	1
Lack of efficacy	4	3	2

Period 4

Period 4 title	Post-Transplant Treated (36 months)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Cyclosporine

Arm description:

Cyclosporine (CsA): tablet, oral

1st month target: 150-300 nanogram/meter (ng/m)

After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)

Arm type	Active comparator
Investigational medicinal product name	Cyclosporine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received cyclosporine 150-300 ng/mL and 100-250 ng/mL at Month 1 and after Month 1, respectively.

Arm title	Belatacept LI
------------------	---------------

Arm description:

Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Arm title	Belatacept MI
Arm description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Number of subjects in period 4	Cyclosporine	Belatacept LI	Belatacept MI
Started	153	176	164
Completed	143	170	158
Not completed	10	6	6
Adverse event, serious fatal	-	2	1
Consent withdrawn by subject	1	-	1
Adverse event, non-fatal	5	1	2
Not specified	-	1	1
Subject no longer meets study criteria	-	-	1
Lack of efficacy	4	1	-
Protocol deviation	-	1	-

Period 5

Period 5 title	Long Term Extension (LTE; 84 months)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Subject

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Cyclosporine
Arm description: Cyclosporine (CsA): tablet, oral 1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	
Arm type	Active comparator
Investigational medicinal product name	Cyclosporine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Subjects received cyclosporine 150-300 ng/mL and 100-250 ng/mL at Month 1 and after Month 1, respectively.

Arm title	Belatacept LI
Arm description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Arm title	Belatacept MI
Arm description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Arm type	Experimental
Investigational medicinal product name	Belatacept
Investigational medicinal product code	BMS-224818
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Subjects received belatacept 10 mg/kg intravenously and a maintenance dose of 5 mg/kg.

Number of subjects in period 5^[2]	Cyclosporine	Belatacept LI	Belatacept MI
Started	136	166	155
Completed	89	136	127
Not completed	47	30	28
Adverse event, serious fatal	9	4	4
Consent withdrawn by subject	5	4	1

Adverse event, non-fatal	13	11	14
Not specified	5	4	5
Administrative Reason By Sponsor	1	1	-
Pregnancy	-	1	2
Poor/Non-compliance	4	1	1
Lost to follow-up	4	1	1
Lack of efficacy	6	3	-

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: The number of subjects starting the period was not consistent with the number completing the preceding period as some subjects discontinued and not opted to participate in long term period due to various reasons.

Baseline characteristics

Reporting groups

Reporting group title	Cyclosporine
Reporting group description:	
Cyclosporine (CsA): tablet, oral	
1st month target: 150-300 nanogram/meter (ng/m)	
After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	
Reporting group title	Belatacept LI
Reporting group description:	
Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Belatacept MI
Reporting group description:	
Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	

Reporting group values	Cyclosporine	Belatacept LI	Belatacept MI
Number of subjects	221	226	219
Age, Customized			
Units: subjects			
Between 18 and 45 years:	110	124	111
Between 46 and 65 years:	101	93	93
> 65 years:	10	9	15
Age Continuous			
Units: years			
arithmetic mean	43.5	42.6	43.6
standard deviation	± 14.3	± 13.4	± 14.6
Gender, Male/Female			
Units: subjects			
Female	56	80	68
Male	165	146	151
Previous Number of Transplant			
Units: Subjects			
0x	208	218	210
1x	9	5	5
2x	0	0	1
Missing	4	3	3

Reporting group values	Total		
Number of subjects	666		
Age, Customized			
Units: subjects			
Between 18 and 45 years:	345		
Between 46 and 65 years:	287		
> 65 years:	34		

Age Continuous Units: years arithmetic mean standard deviation	-		
Gender, Male/Female Units: subjects			
Female	204		
Male	462		
Previous Number of Transplant Units: Subjects			
0x	636		
1x	19		
2x	1		
Missing	10		

End points

End points reporting groups

Reporting group title	Cyclosporine
Reporting group description: Cyclosporine (CsA): tablet, oral 1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	
Reporting group title	Belatacept LI
Reporting group description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Belatacept MI
Reporting group description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Cyclosporine
Reporting group description: Cyclosporine (CsA): tablet, oral 1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	
Reporting group title	Belatacept LI
Reporting group description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Belatacept MI
Reporting group description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Cyclosporine
Reporting group description: Cyclosporine (CsA): tablet, oral 1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	
Reporting group title	Belatacept LI
Reporting group description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Belatacept MI
Reporting group description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Cyclosporine
Reporting group description: Cyclosporine (CsA): tablet, oral 1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	

Reporting group title	Belatacept LI
Reporting group description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Belatacept MI
Reporting group description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Cyclosporine
Reporting group description: Cyclosporine (CsA): tablet, oral 1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250 nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)	
Reporting group title	Belatacept LI
Reporting group description: Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	
Reporting group title	Belatacept MI
Reporting group description: Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)	

Primary: Percent of Subjects Surviving with a Functioning Graft by Month 12

End point title	Percent of Subjects Surviving with a Functioning Graft by Month 12
End point description: Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromolar per liter ($\mu\text{mol/L}$) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the subject underwent retransplant. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.	
End point type	Primary
End point timeframe: Day 1 to Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	92.8 (89.3 to 96.2)	96.5 (94.1 to 98.9)	95.4 (92.7 to 98.2)	

Statistical analyses

Statistical analysis title	Subject and graft survival at Month 12
Statistical analysis description:	
A non-inferiority margin of 10% for the co-primary endpoint of subject and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of subject death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on subject death and/or graft loss in the setting of MMF/steroids/basiliximab.	
Comparison groups	Cyclosporine v Belatacept MI
Number of subjects included in analysis	440
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in percentage
Point estimate	2.7
Confidence interval	
level	Other: 97.3 %
sides	2-sided
lower limit	-2.5
upper limit	8.1

Statistical analysis title	Subject and graft survival at Month 12
Statistical analysis description:	
A non-inferiority margin of 10% for the co-primary endpoint of subject and graft survival was used. Determination of a margin for non-inferiority based on 'preservation of benefit' is not feasible, given the low rate of subject death and/or graft loss in the first year post-transplantation, and the absence of published, adequately sized, parallel-group trials with which to assess the effect of CsA on subject death and/or graft loss in the setting of MMF/steroids/basiliximab.	
Comparison groups	Cyclosporine v Belatacept LI
Number of subjects included in analysis	447
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in percentage
Point estimate	3.7
Confidence interval	
level	Other: 97.3 %
sides	2-sided
lower limit	-1.1
upper limit	9

Primary: Percent of Subjects with a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m² at Month 12 or with a Decrease in mGFR Greater Than or Equal to 10 mL/min/1.73m² From Month 3 to Month 12

End point title	Percent of Subjects with a Composite of Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/Min/1.73 m ² at Month 12 or with a Decrease in mGFR Greater Than or Equal to 10 mL/min/1.73m ² From Month 3 to Month 12
-----------------	--

End point description:

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m² was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 mg/dL. A change in GFR of at least 10 mL/min/1.73 m² was used as the approximate change in SCr of at least 0.3 mg/dL. The change

component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Primary
End point timeframe:	
Month 12; Month 3 to Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	213	214	209	
Units: percentage of subjects				
number (confidence interval 95%)	77.9 (72.4 to 83.5)	54.2 (47.5 to 60.9)	55 (48.3 to 61.8)	

Statistical analyses

Statistical analysis title	Difference between belatacept & CsA renal function
Comparison groups	Cyclosporine v Belatacept LI
Number of subjects included in analysis	427
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0 ^[1]
Method	Chi-squared corrected
Parameter estimate	Difference in percentage
Point estimate	-23.7
Confidence interval	
level	Other: 97.3 %
sides	2-sided
lower limit	-33.3
upper limit	-13.7

Notes:

[1] - A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine

Statistical analysis title	Difference between belatacept & CsA renal function
Comparison groups	Cyclosporine v Belatacept MI
Number of subjects included in analysis	422
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0 ^[2]
Method	Chi-squared corrected
Parameter estimate	Difference in percentage
Point estimate	-22.9

Confidence interval	
level	Other: 97.3 %
sides	2-sided
lower limit	-32.6
upper limit	-12.9

Notes:

[2] - A continuity-corrected Chi-square test at significance level 0.027 was performed for the difference between the belatacept regimen and cyclosporine

Primary: Percent of Subjects Experiencing Acute Rejection (AR) Post-transplant by Month 12

End point title	Percent of Subjects Experiencing Acute Rejection (AR) Post-transplant by Month 12
-----------------	---

End point description:

Acute rejection was defined as a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence was defined if either a or b was satisfied: a: an unexplained rise of serum creatinine $\geq 25\%$ from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology: an international standardized histopathological classification. AR was defined by a renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each subject was counted. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 to Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	7.2 (3.8 to 10.7)	17.3 (12.3 to 22.2)	21.9 (16.4 to 27.4)	

Statistical analyses

Statistical analysis title	Acute Rejection (AR) Post-transplant by Month 12
----------------------------	--

Statistical analysis description:

A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens

Comparison groups	Cyclosporine v Belatacept LI
Number of subjects included in analysis	447
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in percentage
Point estimate	10

Confidence interval	
level	Other: 97.3 %
sides	2-sided
lower limit	3.3
upper limit	17.1

Statistical analysis title	Acute Rejection (AR) Post-transplant by Month 12
-----------------------------------	--

Statistical analysis description:

A 20% margin for non-inferiority was used and provides 99% power to ascertain that the upper bound of the 97.3% 2-sided confidence intervals for the absolute difference between each belatacept regimen and cyclosporine, assuming the true acute rejection rate by 12 months is 15% for all three regimens. The 20% non-inferiority margin was not met in the belatacept MI group.

Comparison groups	Belatacept MI v Cyclosporine
Number of subjects included in analysis	440
Analysis specification	Pre-specified
Analysis type	non-inferiority
Parameter estimate	Difference in percentage
Point estimate	14.7
Confidence interval	
level	Other: 97.3 %
sides	2-sided
lower limit	7.5
upper limit	22.2

Secondary: Mean Value of the Measured Glomerular Filtration Rate (mGFR)

End point title	Mean Value of the Measured Glomerular Filtration Rate (mGFR)
-----------------	--

End point description:

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGRF assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m². The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Months 3, 12, 24	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	201	215	209	
Units: mL/min/1.73m ²				
arithmetic mean (standard deviation)				
Month 3 (n=201, 215, 209)	51.9 (± 21.09)	61.7 (± 25.43)	59.9 (± 28.47)	
Month 12 (n=199, 206, 200)	50.4 (± 18.71)	63.4 (± 27.66)	65 (± 30.02)	
Month 24 (n=185, 199, 192)	50.5 (± 20.52)	67.9 (± 29.9)	65 (± 27.21)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Prevalence of Chronic Allograft Nephropathy (CAN) at Month 12

End point title	Percent of Subjects with Prevalence of Chronic Allograft Nephropathy (CAN) at Month 12
-----------------	--

End point description:

Prevalence of CAN = if subject met any of the following conditions: a: CAN observed in a biopsy either prior to 12 months (including baseline biopsy) or first post 12 months biopsy; b: subject had graft loss during the first year post transplant; c: no biopsy was available post 12 months and CAN not observed in biopsies prior to 12 months, but the measured GFR from Month 3 to Month 12 decreased at least 10 mL/min/1.73m²; d: no biopsy available either prior to or post 12 months, and the measured GFR (incorporated missing data imputation) from Month 3 to Month 12 decreased at least 10 mL/min/1.73m². CAN = All allograft biopsies evaluated for presence and severity of CAN by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Onset of CAN determined by the biopsy date when it was observed. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	219	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	32.4 (26.2 to 38.6)	23.9 (18.3 to 29.5)	18.3 (13.1 to 23.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Serious Adverse Events, Death, Discontinuation Due to Adverse Events by Month 84

End point title	Number of Subjects With Serious Adverse Events, Death, Discontinuation Due to Adverse Events by Month 84
-----------------	--

End point description:

Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. All randomised and transplanted subjects from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE).

End point type	Secondary
----------------	-----------

End point timeframe:

Randomisation to Month 84

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	136	166	155	
Units: subjects				
number (not applicable)				
Deaths	9	7	7	
SAEs	107	113	117	
Discontinued due to SAEs	5	8	6	
Discontinued due to AEs	12	11	14	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Adverse Events of Special Interest by Month 84

End point title	Number of Subjects with Adverse Events of Special Interest by Month 84
-----------------	--

End point description:

Prospectively identified events of special interest which were a subset of all AEs, and were either SAEs or non-serious AEs, included the following categories: Serious Infections and Infestations, Thrombotic/embolic events, and Malignancy. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/ abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Time frame is from randomisation to the event date, or to the last dose date+56, or to Month 84 (Day 2548), whichever is the earliest. The analysis was performed in all randomised and transplanted subjects from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE).

End point type	Secondary
----------------	-----------

End point timeframe:

Randomisation to Month 84

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	136	166	155	
Units: subjects				
number (not applicable)				
Malignancies	22	16	20	
Cytomegalovirus (CMV) Infections	19	24	20	
BK Polyoma Virus Infections	6	10	15	
Herpes Virus Infections	29	37	37	
Fungal Infections	42	47	55	
Tuberculosis Infections	2	1	5	
Central Nervous System (CNS) Infections	0	0	1	
Pulmonary edema or Chronic Heart Failure	12	4	5	
Auto-immune Events	8	8	6	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Blood Pressure at Month 84

End point title	Mean Blood Pressure at Month 84
-----------------	---------------------------------

End point description:

Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the subject arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart. The analysis was performed in all randomised and transplanted subjects from the original intent-to-treat (ITT) population who continued on assigned therapy into the long-term extension phase (ITT-LTE). Here, 'Number of subjects Analysed' signifies subjects evaluable for this outcome measure.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 84

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	82	125	112	
Units: mmHg				
arithmetic mean (standard deviation)				
Diastolic Blood Pressure	78.6 (± 11.03)	75.8 (± 10.56)	75.1 (± 10.15)	
Systolic Blood Pressure	129 (± 15.83)	126.7 (± 18.17)	126 (± 17.56)	

Statistical analyses

Secondary: Number of Subjects Meeting Marked Laboratory Abnormality Criteria Post-transplant by Month 36

End point title	Number of Subjects Meeting Marked Laboratory Abnormality Criteria Post-transplant by Month 36
End point description:	
Upper limit of normal (ULN). Units per Liter (U/L). Cells per microliter (c/μL). Grams per deciliter (g/dL). Milligrams per deciliter (mg/dL). Cells per Liter (c/L). Milliequivalents/Liter (mEq/L). Hemoglobin (low): <8.0 g/dL; Platelet count: <50*10 ⁹ c/L; Leukocytes: <2*10 ³ c/μL; Alkaline phosphatase (ALP): >5.0*ULN U/L; Alanine aminotransferase (ALT): >5.0*ULN U/L; Aspartate aminotransferase (AST): >5.0*ULN U/L; Bilirubin Total: >3.0*ULN mg/dL; Creatinine: >3.0*ULN mg/dL; Calcium Total: low if <7.0 mg/dL or high if >12.5 mg/dL; Bicarbonate: <11.0 mEq/L; Potassium serum: low if <3.0 mEq/L or high if >6.0 mEq/L; Magnesium serum: low is <0.8 mEq/L or high if >2.46 mEq/L; Sodium serum: low if <130.0 mEq/L or high if >155.0 mEq/L; Phosphorus inorganic: <2.0 mg/dL; Albumin: <2 g/dL; Uric acid: >10 mg/dL; Protein urine: >=3+. The analysis was performed in all randomised and transplanted subjects from the original intent-to-treat (ITT) population.	
End point type	Secondary
End point timeframe:	
Baseline to Month 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: subjects				
number (not applicable)				
Hemoglobin, low (n=213, 226, 219)	26	25	27	
Platelet count, low (n=213, 226, 218)	0	1	0	
Leukocytes, low (n=213, 226, 219)	10	5	5	
Alkaline phosphatase, high (n=214, 226, 219)	1	4	0	
Alanine aminotransferase, high (n=214, 226, 219)	6	6	4	
Aspartate aminotransferase, high (n=214, 226, 219)	2	3	3	
Bilirubin total, high (n=214, 226, 219)	1	0	0	
Calcium total, low (n=214, 226, 219)	7	8	4	
Calcium total, high (n=214, 226, 219)	0	1	0	
Bicarbonate, low (n=214, 226, 219)	1	0	0	
Bicarbonate, high (n=214, 226, 219)	0	0	0	
Potassium serum, low (n=213, 223, 219)	4	13	12	
Potassium serum, high (n=213, 223, 219)	13	9	4	
Magnesium serum, low (n=214, 225, 219)	1	2	1	
Magnesium serum, high (n=214, 225, 219)	9	12	14	
Sodium serum, low (n=214, 226, 219)	21	8	9	
Sodium serum, high (n=214, 226, 219)	0	1	0	
Phosphorus inorganic, low (n=213, 224, 219)	75	100	112	
Albumin, low (n=214, 226, 219)	0	0	0	
Uric acid, high (n=214, 226, 219)	42	7	11	

Protein in urine, high (n=213, 224, 217)	33	30	36	
Creatinine, high (n=213, 223, 219)	48	50	52	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects With Development of Anti-Donor HLA Positive Antibodies by Month 84

End point title	Percent of Subjects With Development of Anti-Donor HLA Positive Antibodies by Month 84
End point description:	
Only subjects who had non-missing test result for Class I or Class II anti-donor HLA antibodies were included in analysis and only subjects who had at least one non-NA test result or finding were counted. This was a cumulative summary (excluding baseline) and once a subject was positive, that subject remained positive for the later time point. Acute rejection (AR) defined: a clinico-pathological event requiring clinical evidence and biopsy confirmation. Clinical evidence defined: an unexplained rise of serum creatinine \geq 25% from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. AR defined as allograft biopsies of Banff 97 classification Grade IA or greater (higher scores indicate more severe rejection). Evaluated by blinded central independent pathologist. The analysis was performed in ITT population.	
End point type	Secondary
End point timeframe:	
Randomisation to Month 84	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	215	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	11.6 (7.34 to 15.91)	3.1 (0.84 to 5.36)	1.4 (0.28 to 3.95)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change of the Measured Glomerular Filtration Rate (mGFR) from Month 3 to Month 12 and from Month 3 to Month 24

End point title	Mean Change of the Measured Glomerular Filtration Rate (mGFR) from Month 3 to Month 12 and from Month 3 to Month 24
-----------------	---

End point description:

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. Missing mGFR assessments were imputed to assess renal function. The overall imputation strategy involved a primary imputation method (linear extrapolation and quartile method) followed by 2 secondary imputation methods (regression method and graded

quartile method) to assess the robustness of conclusions obtained from the application of the primary imputation method. All imputation methods entailed replacing a missing value with a value drawn from a plausible distribution incorporating theoretical and observed aspects of the data. GFR was measured as mL/min/1.73 m². The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Month 3 to Month 12; Month 3 to Month 24	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	195	206	200	
Units: mL/min/1.73m ²				
arithmetic mean (standard deviation)				
Baseline (Month 3) to Month 12 (n=195, 206, 200)	-1.7 (± 21.58)	1.2 (± 30.43)	4.4 (± 31.1)	
Baseline (Month 3) to Month 24 (n=184, 199, 192)	-2 (± 25.23)	5.3 (± 33.03)	4.2 (± 30.96)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects With a Decrease in Measured Glomerular Filtration Rate (mGFR) Greater Than or Equal to 10mL/min/1.73m² from Month 3 to Month 12

End point title	Percent of Subjects With a Decrease in Measured Glomerular Filtration Rate (mGFR) Greater Than or Equal to 10mL/min/1.73m ² from Month 3 to Month 12
-----------------	---

End point description:

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A change in GFR of at least 10 mL/min/1.73 m² was used as the approximate change in serum creatinine (SCr) of at least 0.3 mg/dL. The change component of the composite renal endpoint was assessed from Month 3 to Month 12, since post-transplant renal function is largely stable by Month 3. Month 3 = baseline. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Month 3 to Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	213	214	209	
Units: percentage of subjects				
number (confidence interval 95%)	28.2 (22.1 to 34.2)	23.4 (17.7 to 29)	23 (17.3 to 28.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with a Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/min/1.73 m² at Month 12

End point title	Percent of Subjects with a Measured Glomerular Filtration Rate (mGFR) Less Than 60 mL/min/1.73 m ² at Month 12
-----------------	---

End point description:

Measured glomerular filtration rate (mGFR) is the direct measurement of renal function and was assessed by measurement of the clearance of a true glomerular filtration marker (non-radiolabeled iothalamate) using a validated procedure. A GFR of 60 mL/min/1.73 m² was used as the approximate equal of the threshold values of serum creatinine (SCr) of 1.5 milligrams per deciliter (mg/dL). The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	213	214	209	
Units: percentage of subjects				
number (confidence interval 95%)	67.6 (61.3 to 73.9)	43 (36.4 to 49.6)	43.5 (36.8 to 50.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Value of the Calculated Glomerular Filtration Rate (cGFR) with Imputation

End point title	Mean Value of the Calculated Glomerular Filtration Rate (cGFR) with Imputation
-----------------	--

End point description:

Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: $GFR = 170 \times [SCr/0.95]^{(-0.999)} \times [Age]^{(-0.176)} \times [0.762 \text{ if subject is female}] \times [1.180 \text{ if subject is black}] \times [BUN]^{(-0.170)} \times [Alb]^{(+0.318)}$; Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m². The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 6, 12, 24, 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	199	201	201	
Units: mL/min/1.73 m ²				
arithmetic mean (standard deviation)				
Month 6 (n=189, 185, 170)	48.8 (± 19.22)	62.6 (± 20.41)	62.4 (± 20.94)	
Month 12 (n=199, 200, 201)	50.1 (± 21.06)	65.4 (± 22.94)	65.2 (± 23.51)	
Month 24 (n=182, 201, 191)	47.9 (± 23)	65.4 (± 25.22)	65.5 (± 24.87)	
Month 36 (n=171, 190, 186)	44.4 (± 23.58)	65.8 (± 27)	65.2 (± 26.31)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change in Calculated Glomerular Filtration Rate (cGFR) from Month 6 to Month 12

End point title	Mean Change in Calculated Glomerular Filtration Rate (cGFR) from Month 6 to Month 12
-----------------	--

End point description:

Calculated glomerular filtration rate (cGFR) was used to assess renal function (as measured by the estimated creatinine clearance) using the following modification of diet in renal disease (MDRD) formula: MDRD: $GFR = 170 \times [SCr/0.95]^{(-0.999)} \times [Age]^{(-0.176)} \times [0.762 \text{ if subject is female}] \times [1.180 \text{ if subject is black}] \times [BUN]^{(-0.170)} \times [Alb]^{(+0.318)}$; Age in years; Alb = Albumin in g/dL; SCr = Serum creatinine in mg/dL; BUN = Blood urea nitrogen in mg/dL; cGFR = mL/min/1.73m². The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 6 to Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	166	169	160	
Units: mL/Min/1.73 m ²				
arithmetic mean (standard deviation)	2.3 (± 10.09)	4.7 (± 11.52)	5.1 (± 11.37)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Incidence of New Onset Diabetes Mellitus by Month 36

End point title	Percent of Subjects with Incidence of New Onset Diabetes Mellitus by Month 36
End point description:	
The incidence of new onset diabetes mellitus defined as subjects who developed diabetes mellitus after randomization and transplantation. Subjects that did not have diabetes prior to randomization were determined to have new onset diabetes mellitus if (i) the subject received an anti-diabetic medication for a duration of at least 30 days or (ii) at least two fasting plasma glucose (FPG) tests indicate that FPG is ≥ 126 mg/dL (7.0 mmol/L). New onset diabetes mellitus (NODM) = post-transplant diabetes mellitus (PTDM). The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.	
End point type	Secondary
End point timeframe:	
Week 4 post-transplantation to Month 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	162	168	156	
Units: percentage of subjects				
number (confidence interval 95%)				
Month 12	9.9 (5.3 to 14.5)	4.2 (1.1 to 7.2)	7.1 (3 to 11.1)	
Month 24	10.5 (5.8 to 15.2)	5.4 (2 to 8.8)	8.3 (4 to 12.7)	
Month 36	11.1 (6.3 to 16)	6.5 (2.8 to 10.3)	10.3 (5.5 to 15)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects Using At Least One Anti-Hypertensive Medication to Control Hypertension at Month 36

End point title	Percent of Subjects Using At Least One Anti-Hypertensive Medication to Control Hypertension at Month 36
End point description:	
The analysis was based on all subjects who had been followed up at least 1092 days after transplantation. Hypertension was defined in according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mmHg. In addition, all subjects who had a SBP < 130 mmHg and a DBP < 80 mmHg who received an antihypertensive medication(s) for the indication of hypertension or with a medical history of hypertension were included in this definition. Systolic blood pressure = SBP; Diastolic blood pressure = DBP. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.	
End point type	Secondary
End point timeframe:	
Month 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	182	199	192	
Units: percentage of subjects				
number (confidence interval 95%)	92.9 (89.12 to 96.6)	81.9 (76.56 to 87.36)	83.9 (78.65 to 89.06)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Incidence of Hypertension Post-Transplantation at Month 12

End point title	Percent of Subjects with Incidence of Hypertension Post-Transplantation at Month 12
-----------------	---

End point description:

The incidence of hypertension was defined as the proportion of subjects who developed hypertension after randomization and transplantation. Specifically, the incidence of hypertension was assessed only after the Week 4 visit. This period allowed for adequate stabilization and resolution of transient changes. If subjects received antihypertensive medication for the indication of hypertension at this (or later) time point, they were considered to have developed hypertension. Hypertension was defined according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition was based upon SBP ≥ 130 mm Hg or DBP ≥ 80 mm Hg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	13	7	
Units: percentage of subjects				
number (confidence interval 95%)	75 (19.4 to 99.4)	53.8 (26.7 to 80.9)	57.1 (18.4 to 90.1)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects With Prevalence of Hypertension Post-Transplantation at Month 12

End point title	Percent of Subjects With Prevalence of Hypertension Post-Transplantation at Month 12
-----------------	--

End point description:

The prevalence of hypertension was defined as the proportion of subjects at any given time who meet the definition of hypertension. Hypertension defined according to the Seventh Report of the Joint

National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure for subjects with chronic kidney disease. This definition is based upon SBP \geq 130 mmHg or DBP \geq 80 mmHg. Systolic blood pressure = SBP; Diastolic blood pressure = DBP. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	91 (87.17 to 94.73)	89.8 (85.88 to 93.76)	88.6 (84.37 to 92.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Systolic Blood Pressure and Diastolic Blood Pressure

End point title	Mean Systolic Blood Pressure and Diastolic Blood Pressure
End point description:	
Blood pressure was measured in millimeters of mercury (mmHg). Blood pressure was measured soon after the subject arrived and sat quietly at rest for 10 minutes. 3 consecutive seated blood pressure readings were made at least 1 minute apart. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.	
End point type	Secondary
End point timeframe:	
Months 12, 24, 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	188	193	191	
Units: mmHg				
arithmetic mean (standard deviation)				
Systolic; Month 12 (n=188, 193, 191)	138.7 (\pm 19.98)	131.4 (\pm 16.54)	132.7 (\pm 16.21)	
Diastolic; Month 12 (n=188, 193, 191)	81.9 (\pm 11.1)	78.7 (\pm 10.91)	79.3 (\pm 11.54)	
Systolic; Month 24 (n=160, 185, 174)	135.4 (\pm 19.71)	130.5 (\pm 17.35)	129.8 (\pm 16.84)	
Diastolic; Month 24 (n=160, 185, 174)	80.3 (\pm 10.2)	78.3 (\pm 10.51)	77.8 (\pm 10.31)	
Systolic; Month 36 (n=145, 180, 166)	133.5 (\pm 17.93)	127.7 (\pm 16.48)	126 (\pm 16.14)	
Diastolic; Month 36 (n=145, 180, 166)	79.5 (\pm 9.16)	76.6 (\pm 9.75)	76.1 (\pm 11.2)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects at Baseline with Controlled Hypertension Post Transplantation by Month 12

End point title	Percent of Subjects at Baseline with Controlled Hypertension Post Transplantation by Month 12
-----------------	---

End point description:

Controlled hypertension was defined as a SBP < 130 mm Hg and a DBP < 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Subjects with a SBP < 130 mm Hg and a DBP < 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1 to Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	182	182	183	
Units: percentage of subjects				
number (confidence interval 95%)	21.4 (15.5 to 27.4)	28.6 (22 to 35.1)	24.6 (18.4 to 30.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Prevalence of Controlled Hypertension at Month 12

End point title	Percent of Subjects with Prevalence of Controlled Hypertension at Month 12
-----------------	--

End point description:

The prevalence of controlled hypertension was defined as the proportion of subjects at any given time who met the definition of controlled hypertension. Controlled hypertension was defined as a SBP < 130 mm Hg and a DBP < 80 mm Hg while receiving an antihypertensive medication for the indication of hypertension or receiving an antihypertensive medication for another indication with a medical history of hypertension. Subjects with a SBP < 130 mm Hg and a DBP < 80 mm Hg who were prescribed an antihypertensive medication(s) for an indication(s) other than hypertension (eg, beta blockers for migraine prophylaxis) with no medical history of hypertension were not considered to have either hypertension or controlled hypertension. Systolic blood pressure = SBP; Diastolic blood pressure = DBP.

The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	186	193	190	
Units: percentage of subjects				
arithmetic mean (confidence interval 95%)	21 (15.12 to 26.82)	28 (21.65 to 34.31)	24.7 (18.6 to 30.87)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Non-dyslipidemic Subjects With Incidence of Dyslipidemia Post-Transplantation by Month 12

End point title	Percent of Non-dyslipidemic Subjects With Incidence of Dyslipidemia Post-Transplantation by Month 12
-----------------	--

End point description:

Incidence of dyslipidemia was defined as the proportion of subjects who developed dyslipidemia after randomization and transplantation. Dyslipidemia was defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia = hypertriglyceridemia (TGs \geq 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL \geq 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL \geq 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs \geq 200 mg/dL [2.26 mmol/L]). The TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if $N \geq 5$. Otherwise exact method is used. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Randomisation to Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	75	94	79	
Units: percentage of subjects				
number (confidence interval 95%)	80 (70.9 to 89.1)	63.8 (54.1 to 73.5)	70.9 (60.9 to 80.9)	

Statistical analyses

Secondary: Percent of Subjects With Prevalence of Dyslipidemia at Month 12

End point title	Percent of Subjects With Prevalence of Dyslipidemia at Month 12
-----------------	---

End point description:

The prevalence of dyslipidemia was defined as the proportion of subjects at any given time who met the definition of dyslipidemia. Dyslipidemia defined in accordance with recent guidelines from the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). Dyslipidemia defined as hypertriglyceridemia (TGs \geq 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL \geq 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL \geq 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs \geq 200 mg/dL [2.26 mmol/L]). TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if $N \geq 5$. Otherwise exact method is used. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	52.9 (46.4 to 59.5)	44.7 (38.2 to 51.2)	46.1 (39.5 to 52.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects With Controlled Dyslipidemia at Month 12

End point title	Percent of Subjects With Controlled Dyslipidemia at Month 12
-----------------	--

End point description:

Prevalence of controlled dyslipidemia = the percentage of subjects at any given time who met the stated definition of dyslipidemia. Dyslipidemia as per National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) was defined as hypertriglyceridemia (TGs \geq 500 milligrams/deciliter (mg/dL) [5.65 mmol/L]), hypercholesterolemia (LDL \geq 100 mg/dL [2.59 mmol/L]), or elevated non-HDL (non-HDL \geq 130 mg/dL [3.36 mmol/L]) in the presence of high TGs (TGs \geq 200 mg/dL [2.26 mmol/L]). Controlled dyslipidemia defined as subjects who received successful pharmacologic treatment for 1 of the above stated dyslipidemias, and their lipid values fell below the thresholds described. TG = triglyceride; LDL = low density lipoprotein; HDL = high density lipoprotein; millimole/Liter (mmol/L). For 95% CI within each group, normal approximation is used if $N \geq 5$. Otherwise exact method is used. Analysis was performed in intent-to-treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	18.1 (13 to 23.2)	15.5 (10.8 to 20.2)	15.5 (10.7 to 20.3)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects With Antihyperlipidemic Medication by Intensity Level

End point title	Number of Subjects With Antihyperlipidemic Medication by Intensity Level
-----------------	--

End point description:

An intensity level was associated with dose level of statin based anti-hyperlipidemic agent. Any other agent (i.e., non-statin therapy) used as an antihyperlipidemic were considered Level I treatment intensity. Multiple daily doses were averaged to compute daily dose during that period. Level I = 20 mg fluvastatin (flu), 10 mg lovastatin (lova), 10 mg pravastatin (prav), 5-10 mg simvastatin (sim); Level II = 10 mg atorvastatin (atorv), 40 mg flu, 20 mg lova, 20 mg prav, 5 mg rosuvastatin (rosu), 20 mg sim, 10/10 vytorin; Level III = 20 mg atorv, 80 mg flu, 40 mg lova, 40 mg prav, 10 mg rosu, 40 mg sim, 10/20 vytorin; Level IV = 40 mg atorv, 80 mg lova, 80 mg prav, 20 mg rosu, 80 mg sim, 10/40 vytorin; Level V = 80 mg atorv, 40 mg rosu, 10/80 vytorin. Concomitant use of a statin and an agent of another class elevated the intensity level of the statin therapy by 1 level; therefore, an intensity level of greater than V was possible. Analysis was performed in ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	103	92	92	
Units: subjects				
number (not applicable)				
Intensity Level I	17	15	17	
Intensity Level II	46	27	39	
Intensity Level III	27	32	23	
Intensity Level IV	8	16	9	
Intensity Level V	4	1	4	
Intensity Level VI	1	1	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects Using At Least One Anti-Hyperlipidemic Medication

End point title	Percent of Subjects Using At Least One Anti-Hyperlipidemic Medication
-----------------	---

End point description:

This analysis is based on all subjects who were followed up at least 1092 days after transplantation. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population. Completer analysis is based on all subjects who have been followed up at least 1092 days after transplantation.

End point type	Secondary
----------------	-----------

End point timeframe:

Month 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	182	199	192	
Units: percentage of subjects				
number (confidence interval 95%)	56.6 (49.4 to 63.8)	46.2 (39.3 to 53.2)	47.9 (40.9 to 55)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Value of Lipid Parameters

End point title	Mean Value of Lipid Parameters
-----------------	--------------------------------

End point description:

Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, and triglycerides (TGs). The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 12, 24, 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	189	195	192	
Units: mg/dL				
arithmetic mean (standard deviation)				
non-HDL Cholesterol; Month 12 (n=189, 195, 192)	144.1 (± 47.31)	131.5 (± 38.18)	131.7 (± 36.76)	
Total Cholesterol; Month 12 (n=189, 195, 192)	191.5 (± 49.29)	182.4 (± 39.78)	181.3 (± 39.92)	
HDL Cholesterol; Month 12 (n=189, 195, 192)	47.4 (± 13.33)	50.8 (± 15.98)	49.7 (± 15.69)	
LDL Cholesterol; Month 12 (n=187, 186, 183)	107.3 (± 39.6)	102.1 (± 33.4)	100.8 (± 29.48)	

Triglyceride; Month 12 (n=187, 186, 183)	184.6 (± 106.42)	149.4 (± 87.25)	155 (± 85.08)	
non-HDL Cholesterol; Month 24 (n=166, 190, 181)	145.1 (± 39.52)	126.7 (± 38.48)	127 (± 36.76)	
Total Cholesterol; Month 24 (n=166, 190, 181)	193.5 (± 40.23)	175.3 (± 42.38)	175.4 (± 40.03)	
HDL ; Month 24 (n=166, 190, 181)	48.4 (± 13.74)	48.6 (± 15.28)	48.5 (± 14.92)	
LDL Cholesterol; Month 24 (n=164, 186, 168)	109.1 (± 35.92)	98.6 (± 33.71)	96.5 (± 30.52)	
Triglyceride; Month 24 (n=164, 186, 168)	179.5 (± 97.51)	143.4 (± 88.97)	151.2 (± 95.88)	
non-HDL Cholesterol; Month 36 (n=154, 184, 176)	142.2 (± 43.19)	122.4 (± 40.12)	122.1 (± 38.78)	
Total Cholesterol; Month 36 (n=154, 184, 176)	190.7 (± 45.28)	171.3 (± 45.78)	170.7 (± 43.26)	
HDL Cholesterol; Month 36 (n=154, 184, 176)	48.5 (± 14.27)	48.9 (± 15.37)	48.6 (± 16.86)	
LDL Cholesterol; Month 36 (n=142, 170, 161)	107.6 (± 37.66)	96.7 (± 36.53)	92.5 (± 33.78)	
Triglyceride; Month 36 (n=142, 170, 161)	179.1 (± 97.07)	132.7 (± 68.69)	144 (± 81.48)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Prevalence of Acute Rejection (AR) by Month 36

End point title	Percent of Subjects with Prevalence of Acute Rejection (AR) by Month 36
-----------------	---

End point description:

Prevalence of AR = subjects with the stated definition of AR at any given time. AR=clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each subject was counted. Clinical evidence=if either a or b was satisfied: a: an unexplained rise of serum creatinine $\geq 25\%$ from baseline creatinine; b: an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. ITT Population was analysed.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomization to Month 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)				
Month 6 (n=221, 226, 219)	5.4 (2.4 to 8.4)	16.8 (11.9 to 21.7)	21.9 (16.4 to 27.4)	

Month 24 (n=221, 226, 219)	9 (5.3 to 12.8)	17.3 (12.3 to 22.2)	24.2 (18.5 to 29.9)	
Month 36 (n=221, 226, 219)	9.5 (5.6 to 13.4)	17.3 (12.3 to 22.2)	24.2 (18.5 to 29.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects with Acute Rejection (AR) Post-transplant in Terms of Severity using Banff Grades by Month 36

End point title	Number of Subjects with Acute Rejection (AR) Post-transplant in Terms of Severity using Banff Grades by Month 36
-----------------	--

End point description:

Acute rejection was defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined: if either a or b was satisfied: a) an unexplained rise of serum creatinine $\geq 25\%$ from baseline creatinine; b) an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Banff 97 diagnostic category for renal allograft biopsies is an international standardized histopathological classification. Only the episode with the highest Banff grade for each subject was counted. Analysis was performed in all randomised and transplanted subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomisation to Month 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: subjects				
number (not applicable)				
Mild Acute (IA); Month 6	1	4	7	
Mild Acute (IB); Month 6	5	9	3	
Moderate Acute (IIA); Month 6	5	14	16	
Moderate Acute (IIB); Month 6	1	10	20	
Severe Acute (III); Month 6	0	1	2	
Mild Acute (IA); Month 12	3	4	7	
Mild Acute (IB); Month 12	5	8	3	
Moderate Acute (IIA); Month 12	6	16	17	
Moderate Acute (IIB); Month 12	2	10	20	
Severe Acute (III); Month 12	0	1	2	
Mild Acute (IA); Month 24	4	4	7	
Mild Acute (IB); Month 24	7	8	3	
Moderate Acute (IIA); Month 24	6	16	18	
Moderate Acute (IIB); Month 24	3	10	22	
Severe Acute (III); Month 24	0	1	3	
Mild Acute (IA); Month 36	5	4	7	
Mild Acute (IB); Month 36	7	8	3	

Moderate Acute (IIA); Month 36	6	16	18	
Moderate Acute (IIB); Month 36	3	10	22	
Severe Acute (III); Month 36	0	1	3	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects Using Polyclonal Antilymphocyte Preparations for Impaired Renal Function and Anticipated Delayed Graft Function by Month 12

End point title	Percent of Subjects Using Polyclonal Antilymphocyte Preparations for Impaired Renal Function and Anticipated Delayed Graft Function by Month 12
-----------------	---

End point description:

Subject were considered to have delayed graft function (DGF), if treated with dialysis within the first week (Day 1 - 8) after transplantation. Use of polyclonal antilymphocyte preparations (LDT) was permitted only for subjects randomised to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated DGF following transplantation and were not permitted in belatacept-treated subjects, except for the treatment of acute rejection. Subjects treated with LDT began CsA at the discretion of the investigator by Day 7. LDT could also have been used in subjects who met ≥ 1 of the following criteria, observed in the presence of a transplant artery and vein and no evidence of hydronephrosis by sonogram: Urine output < 250 mL/12 hours, no significant improvement (< 1 milligram per deciliter (mg/dL)) in serum creatinine from baseline value over the first 24 - 72 hours post-transplant, or dialysis treatment. Analysis was performed in all randomised and transplanted subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomisation to Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)	3.6 (1.2 to 6.1)	0.4 (0 to 2.4)	0.5 (0 to 2.5)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects Using Lymphocyte Depleting Therapy (LDT) for the Initial Treatment of Acute Rejection (AR) by Month 36

End point title	Percent of Subjects Using Lymphocyte Depleting Therapy (LDT) for the Initial Treatment of Acute Rejection (AR) by Month 36
-----------------	--

End point description:

LDT (thymoglobulin or antithymocyte gamma globulin [ATGAM]) was permitted only for subjects randomized to cyclosporine (CsA) who experienced impaired renal allograft function and anticipated delayed graft function post transplantation. Acute rejection (AR) defined as clinico-pathological event requiring clinical evidence (an unexplained rise of serum creatinine $\geq 25\%$ from baseline or an

unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed) and biopsy confirmation. AR defined by renal biopsy demonstrating a Banff 97 classification of Grade IA or greater, higher scores indicating more severe rejection. Banff 97 category is an international standardized histopathological classification. Only the episode with the highest Banff grade for each subject was counted. Analysis was per performed in all randomised and transplanted subjects.

End point type	Secondary
End point timeframe:	
Randomisation to Month 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (not applicable)				
Month 6	0.5	4.4	5.9	
Month 12	0.9	4.4	5.9	
Month 24	1.4	4.4	5.9	
Month 36	1.8	4.4	5.9	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Corticosteroid resistant Acute Rejection (AR) by Month 36

End point title	Percent of Subjects with Corticosteroid resistant Acute Rejection (AR) by Month 36
-----------------	--

End point description:

Steroid-resistant acute rejection (AR) defined as use of lymphocyte-depletion therapy following treatment with corticosteroids. AR defined as clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Clinical evidence defined as an unexplained rise of serum creatinine $\geq 25\%$ from baseline creatinine; or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 international standardized histopathological working classification of kidney transplant pathology. Only the episode with the highest Banff grade for each subject was counted. Analysis was per performed in all randomised and transplanted subjects.

End point type	Secondary
End point timeframe:	
Randomisation to Month 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (not applicable)				
Month 6	0	4	5.9	
Month 12	0	5.3	6.4	
Month 24	0.5	5.3	6.4	
Month 36	0.5	5.3	6.8	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Who Recovered Completely from an Episode of Acute Rejection (AR) by Month 12

End point title	Number of Subjects Who Recovered Completely from an Episode of Acute Rejection (AR) by Month 12
-----------------	---

End point description:

Acute rejection (AR)= clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater. Clinical evidence = unexplained rise of serum creatinine $\geq 25\%$ from baseline; or unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remains elevated within 14 days post-transplantation and clinical suspicion of acute rejection exists. Complete recovery following AR defined as serum creatinine [SCr] levels returned to baseline. Recovery calculated using 2 algorithms: Algorithm 1 = last laboratory measurement prior to onset of AR (baseline and first laboratory measurement after 84 days since onset of AR = resolution); Algorithm 2 = lowest lab measurement on or after transplantation and prior to onset day of AR (baseline and lowest laboratory measurement after onset on first AR up to Month 12 = resolution). Analysis was performed in all randomised and transplanted subjects.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomisation to Month 12

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	16	39	48	
Units: subjects				
number (not applicable)				
Algorithm 1	13	29	39	
Algorithm 2	13	34	43	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Subclinical Rejection at Month 12

End point title	Percent of Subjects with Subclinical Rejection at Month 12
End point description:	
Subclinical rejection defined as histological findings by the central pathologist consistent with acute rejection, but lacking its clinical correlate. Acute rejection defined as a clinico-pathological event requiring clinical evidence and renal biopsy confirmation demonstrating a Banff 97 classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the episode with the highest Banff grade for each subject was counted. Clinical evidence defined as an unexplained rise of serum creatinine $\geq 25\%$ from baseline; or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of acute rejection existed. Allograft biopsies were evaluated by a blinded central independent pathologist using Banff 97 working classification of kidney transplant pathology. Analysis was performed in all randomised and transplanted subjects.	
End point type	Secondary
End point timeframe:	
Month 12	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	155	170	164	
Units: percentage of subjects				
number (confidence interval 95%)	5.2 (1.7 to 8.6)	4.7 (1.5 to 7.9)	4.3 (1.2 to 7.4)	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Subjects Treated for Acute Rejection (AR) Regardless of Histological Findings by Month 36

End point title	Number of Subjects Treated for Acute Rejection (AR) Regardless of Histological Findings by Month 36
End point description:	
Allograft rejection includes any episode of rejection: clinically suspected rejection, treated rejection, any central biopsy-proven acute rejection (BPAR), and acute rejection (AR: a subset of BPAR) defined as central biopsy-proven rejection that was either clinically suspected by protocol-defined reasons or by other reasons and was treated. AR defined as clinico-pathological event requiring clinical evidence (either an unexplained rise of serum creatinine $\geq 25\%$ from baseline or an unexplained decreased urine output; or fever and graft tenderness; or a serum creatinine that remained elevated within 14 days post-transplantation and clinical suspicion of AR) and renal biopsy confirmation biopsy demonstrating a Banff 97 classification of kidney transplant pathology classification of Grade IA or greater, with higher scores indicating more severe rejection. Only the highest Banff grade for each subject was counted. Analysis was performed in all randomised and transplanted subjects.	
End point type	Secondary
End point timeframe:	
Randomisation to Month 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: subjects				
number (not applicable)				
Month 6	43	68	70	
Month 12	56	72	75	
Month 24	63	74	81	
Month 36	69	76	82	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Value of Physical and Mental Components using SF-36 Questionnaire

End point title	Mean Value of Physical and Mental Components using SF-36 Questionnaire
-----------------	--

End point description:

The SF-36 was a Subject-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The scale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The scale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The scale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 6, 12, 24, 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	203	218	201	
Units: units on a scale				
arithmetic mean (standard deviation)				
Mental Component Score; Month 6 (n=191, 205, 189)	49.4 (± 11.08)	49.9 (± 10.55)	51.1 (± 10.53)	
Physical Component Score; Month 6 (n=191,205,189)	47.3 (± 8.91)	48.9 (± 8.59)	49.2 (± 7.58)	
Mental Component Score; Month 12 (n=198,210,194)	49.5 (± 10.78)	50.3 (± 10.08)	49.9 (± 10.54)	
Physical Component Score; Month 12 (n=198,210,194)	47.5 (± 9.34)	49.6 (± 8.18)	50.3 (± 8.21)	
Mental Component Score; Month 24 (n=200,214,198)	48.3 (± 11.14)	49.6 (± 10.77)	48.8 (± 11.03)	
Physical Component Score; Month 24 (n=200,214,198)	47.3 (± 9.5)	49 (± 8.77)	49.9 (± 8.03)	
Mental Component Score; Month 36 (n=203,218,201)	46.9 (± 11.6)	48.7 (± 11.26)	48.3 (± 11.5)	
Physical Component Score; Month 36 (n=203,218,201)	47.1 (± 9.47)	49.2 (± 9.15)	48.7 (± 8.9)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire

End point title	Mean Value of the Eight Domain Scores of Quality of Life Using SF-36 Questionnaire
End point description:	
Subject-Reported questionnaire (8 Domains): Bodily Pain (1=none to 6=very severe;Pain interfered with normal work 1=not at all to 6=extremely),General Health (1=excellent/better than 1 year ago to 5=poor /much worse than 1 year ago), Mental Health (involving emotions 1=all of the time and 6= none of the time;emotional problems interfered with normal activities 1=not at all and 5= extremely.), Physical Functioning (1 to 3 with 1=Yes,limited a lot and 3=No,not limited at all;physical health interfered with normal activities 1=not at all and 5= extremely. Role Emotional (emotional problems interfered 1=all time to 5=none of time),Role Physical (physical problems interfered 1=all time to 5=none of time),Social Functioning (interference in social activities 1=not at all to 5=extremely),Vitality: I get sick easier;I'm healthy as anyone;health excellent;expect health to worsen:1=definitely true,2=mostly true, don't know=3,mostly false=4,definitely false=5. Analysis = ITT population.	
End point type	Secondary
End point timeframe:	
Months 6, 12, 24, 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	205	219	206	
Units: units on a scale				
arithmetic mean (standard deviation)				
Bodily Pain, Month 6 (n=193, 207, 193)	50.6 (± 10.96)	52.5 (± 10.1)	52.7 (± 10.04)	
General Health, Month 6 (n=193, 207, 194)	47.9 (± 10.08)	48.2 (± 9.67)	49 (± 8.66)	
Mental Health, Month 6 (n=192, 206, 194)	50.1 (± 11.08)	50.3 (± 10.33)	51.3 (± 10.78)	
Physical Functioning, Month 6 (n=193, 207, 194)	47.4 (± 9.13)	48.3 (± 9.01)	48 (± 8.81)	
Role Emotional, Month 6 (n=192, 206, 191)	44.6 (± 12.31)	46 (± 11.19)	46.8 (± 10.55)	
Role-Physical, Month 6 (n=192, 207, 192)	43.2 (± 11.08)	45.2 (± 10.34)	46.7 (± 9.06)	
Social Functioning, Month 6 (n=193, 207, 194)	47.5 (± 10.68)	47.8 (± 10.41)	47.9 (± 10.65)	
Vitality, Month 6 (n=192, 206, 194)	54 (± 10.27)	55.5 (± 9.75)	56.2 (± 9.29)	
Bodily Pain, Month 12 (n=200, 213, 199)	50.8 (± 10.79)	52.7 (± 9.67)	53.7 (± 9.6)	
General Health, Month 12 (n=200, 214, 199)	46.9 (± 9.98)	48.8 (± 9.57)	49.2 (± 8.85)	
Mental Health, Month 12 (n=200, 213, 199)	49.8 (± 10.99)	50.7 (± 10.64)	50.3 (± 10.29)	

Physical Functioning, Month 12 (n=200, 214, 198)	47.2 (± 9.77)	49 (± 8.88)	48.1 (± 9.84)
Role Emotional, Month 12 (n=198, 213, 196)	45.8 (± 11.36)	46.8 (± 10.82)	45.9 (± 11.27)
Role-Physical, Month 12 (n=199, 213, 196)	45 (± 10.78)	47.1 (± 10)	47.5 (± 9.9)
Social Functioning, Month 12 (n=200, 213, 199)	47.6 (± 10.26)	48.4 (± 9.61)	49.1 (± 9.8)
Vitality, Month 12 (n=200, 213, 199)	53.3 (± 10.01)	55.7 (± 9.81)	56 (± 9.34)
Bodily Pain, Month 24 (n=203, 219, 205)	51 (± 10.82)	51.4 (± 10.51)	52.5 (± 10.47)
General Health, Month 24 (n=203, 219, 205)	46.2 (± 10.07)	48.4 (± 9.61)	48.7 (± 9.45)
Mental Health, Month 24 (n=201, 215, 199)	48.5 (± 11.13)	49.7 (± 10.89)	49.3 (± 10.85)
Physical Functioning, Month 24 (n=203, 219, 205)	46.5 (± 10.69)	48.7 (± 9.76)	48 (± 10.24)
Role Emotional, Month 24 (n=202, 218, 205)	44.8 (± 12.54)	46.4 (± 10.89)	46 (± 10.88)
Role-Physical, Month 24 (n=203, 219, 204)	44.1 (± 11.61)	46.6 (± 10.39)	48 (± 9.33)
Social Functioning, Month 24 (n=203, 219, 205)	47.3 (± 10.64)	48.6 (± 10.28)	47.7 (± 10.23)
Vitality, Month 24 (n=201, 215, 200)	52.5 (± 10.58)	54.5 (± 10.3)	54.2 (± 10.3)
Bodily Pain, Month 36 (n=204, 219, 205)	50 (± 11.4)	52.3 (± 10.4)	51 (± 11.05)
General Health, Month 36 (n=205, 219, 206)	45.5 (± 10.12)	47.7 (± 10.45)	47.5 (± 9.93)
Mental Health, Month 36 (n=203, 219, 204)	47.4 (± 11.64)	48.9 (± 11.52)	48.7 (± 11.43)
Physical Functioning, Month 36 (n=204, 218, 206)	46.8 (± 9.92)	48.1 (± 10.22)	47.8 (± 10.12)
Role Emotional, Month 36 (n=204, 219, 205)	43.5 (± 12.18)	46 (± 11.85)	45.3 (± 11.67)
Role-Physical, Month 36 (n=204, 219, 205)	43.6 (± 10.73)	46.3 (± 11.03)	46.2 (± 10.03)
Social Functioning, Month 36 (n=204, 219, 206)	46.6 (± 10.68)	48.1 (± 10.28)	47.1 (± 10.66)
Vitality, Month 36 (n=203, 219, 204)	51.4 (± 10.48)	53.6 (± 11.38)	53.4 (± 10.46)

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Relative to an Identified Distribution (ridit) Value of Symptom Occurrence and Symptom Distress using Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSDS-59R)

End point title	Mean Relative to an Identified Distribution (ridit) Value of Symptom Occurrence and Symptom Distress using Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSDS-59R)
-----------------	--

End point description:

Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-59R) was used to assess occurrence (never, occasionally, regularly, almost always, always) and distress (0=no distress to 4=terrible distress) of symptoms associated with immunosuppressive therapies. Ridit (relative to an identified distribution) analysis (Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, Inc. 1991) was used. Ridit scores were calculated at baseline and at 6, 12, 24, and 36 months for overall symptom occurrence score and overall symptom distress. Ridit score reflects the

probability that a score observed for an individual randomly selected from a group would be higher (worse symptom) than a score observed for a randomly selected individual from the reference group. Reference group was constituted by the frequency distribution of responses of all subjects on all items at baseline. Redit of the reference group is by definition, 0.5. Analysis = ITT population.

End point type	Secondary
End point timeframe:	
Months 6, 12, 24, 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	186	197	187	
Units: Redit score				
arithmetic mean (standard error)				
Symptom Distress, Month 6 (n=157, 164, 155)	0.4643 (± 0.00452)	0.4407 (± 0.00404)	0.4451 (± 0.00422)	
Symptom Occurrence, Month 6 (n=166, 176, 165)	0.4721 (± 0.00463)	0.4495 (± 0.00425)	0.4459 (± 0.00432)	
Symptom Distress, Month 12 (n=169, 185, 169)	0.4751 (± 0.00453)	0.451 (± 0.00397)	0.4546 (± 0.00421)	
Symptom Occurrence, Month 12 (n=173, 188, 173)	0.4776 (± 0.00458)	0.4519 (± 0.00411)	0.4525 (± 0.0043)	
Symptom Distress, Month 24 (n=182, 195, 179)	0.4798 (± 0.00443)	0.4584 (± 0.00397)	0.4646 (± 0.00424)	
Symptom Occurrence, Month 24 (n=184, 197, 184)	0.4804 (± 0.00446)	0.4574 (± 0.00406)	0.4593 (± 0.00423)	
Symptom Distress, Month 36 (n=184, 196, 183)	0.5 (± 0.00456)	0.4746 (± 0.00408)	0.4892 (± 0.00442)	
Symptom Occurrence, Month 36 (n=186, 197, 187)	0.5 (± 0.00459)	0.4732 (± 0.00421)	0.4846 (± 0.00441)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Changes in the Value of Physical and Mental Components Using SF-36 from Baseline Up To Months 6, 12, 24, and 36

End point title	Mean Changes in the Value of Physical and Mental Components Using SF-36 from Baseline Up To Months 6, 12, 24, and 36
-----------------	--

End point description:

The SF-36 was a Subject-Reported Quality of Life (QoL) Short Form (SF) questionnaire. The scale in the mental component (MCS) part of the instrument ranged from 1 to 6 with 1=all of the time and 6= none of the time. The scale for physical component (PCS) ranged from 1 to 3 with 1=Yes, limited a lot and 3=No, not limited at all. The scale for the extent that physical health or emotional problems interfered with normal activities ranged from 1 to 5 with 1=not at all and 5= extremely. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
End point timeframe:	
Baseline to Months 6, 12, 24, and 36	

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	192	203	193	
Units: units on a scale				
arithmetic mean (standard deviation)				
Mental Component Score; Month 6 (n=187, 197, 184)	5.4 (± 0.714)	6.2 (± 0.695)	7.3 (± 0.72)	
Physical Component Score; Month 6 (n=187, 197, 184)	5 (± 0.58)	6.2 (± 0.566)	6.7 (± 0.585)	
Mental Component Score; Month 12 (n=192, 200, 189)	5.4 (± 0.687)	6.8 (± 0.673)	6.2 (± 0.693)	
Physical Component Score; Month 12 (n=192,200,189)	5.5 (± 0.589)	7.1 (± 0.577)	7.8 (± 0.594)	
Mental Component Score; Month 24 (n=191,202,193)	4.4 (± 0.732)	5.7 (± 0.712)	5.1 (± 0.728)	
Physical Component Score; Month 24 (n=191,202,193)	5.1 (± 0.601)	6.5 (± 0.584)	7.3 (± 0.597)	
Mental Component Score; Month 36 (n=190,203,191)	2.6 (± 0.756)	5.1 (± 0.732)	4.5 (± 0.754)	
Physical Component Score; Month 36 (n=190,203,191)	4.9 (± 0.633)	6.5 (± 0.612)	6.1 (± 0.631)	

Statistical analyses

No statistical analyses for this end point

Secondary: Mean Change in the Value of the Eight Domain Scores Using SF-36 from Baseline Up To Months 6, 12, 24, and 36

End point title	Mean Change in the Value of the Eight Domain Scores Using SF-36 from Baseline Up To Months 6, 12, 24, and 36
-----------------	--

End point description:

Subject-Reported questionnaire (8 Domains): Bodily Pain (1=none to 6=very severe;Pain interfered with normal work 1=not at all to 6=extremely),General Health (1=excellent/better than 1 year ago to 5=poor /much worse than 1 year ago), Mental Health (involving emotions 1=all of the time and 6= none of the time;emotional problems interfered with normal activities 1=not at all and 5= extremely.), Physical Functioning (1 to 3 with 1=Yes,limited a lot and 3=No,not limited at all;physical health interfered with normal activities 1=not at all and 5= extremely. Role Emotional (emotional problems interfered 1=all time to 5=none of time),Role Physical (physical problems interfered 1=all time to 5=none of time),Social Functioning (interference in social activities 1=not at all to 5=extremely),Vitality: I get sick easier;I'm healthy as anyone;health excellent;expect health to worsen:1=definitely true,2=mostly true, don't know=3,mostly false=4,definitely false=5. Analysis = ITT population.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline to Months 6, 12, 24, and 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	194	207	197	
Units: units on a scale				
arithmetic mean (standard error)				
Bodily Pain, Month 6 (n=189,201,189)	2.9 (± 0.712)	4.5 (± 0.691)	4.6 (± 0.712)	

General Health, Month 6 (n=189,201,190)	6.7 (± 0.631)	7.1 (± 0.612)	7.3 (± 0.63)
Mental Health, Month 6 (n=188,198,190)	4.7 (± 0.716)	5.2 (± 0.698)	6.1 (± 0.712)
Physical Functioning, Month 6 (n=189,201,190)	4.7 (± 0.61)	5.3 (± 0.592)	5.6 (± 0.61)
Role Emotional, Month 6 (n=188,200,186)	4.7 (± 0.767)	5.8 (± 0.744)	6.9 (± 0.772)
Role-Physical, Month 6 (n=188,201,187)	6.4 (± 0.718)	8.4 (± 0.694)	9.6 (± 0.72)
Social Functioning, Month 6 (n=189,201,190)	6 (± 0.724)	6.8 (± 0.702)	6.9 (± 0.722)
Vitality, Month 6 (n=188,198,190)	7.5 (± 0.668)	9 (± 0.651)	9.9 (± 0.665)
Bodily Pain, Month 12 (n=194,205,195)	3.1 (± 0.665)	4.8 (± 0.647)	5.5 (± 0.664)
General Health, Month 12 (n=194,206,195)	6 (± 0.638)	7.7 (± 0.619)	7.6 (± 0.636)
Mental Health, Month 12 (n=194,203,195)	4.4 (± 0.685)	6 (± 0.67)	5 (± 0.684)
Physical Functioning, Month 12 (n=194,206,194)	4.7 (± 0.64)	6.2 (± 0.621)	5.8 (± 0.641)
Role Emotional, Month 12 (n=192,205,191)	5.7 (± 0.765)	6.6 (± 0.741)	5.9 (± 0.768)
Role-Physical, Month 12 (n=193,205,191)	8.3 (± 0.716)	10.3 (± 0.695)	10.4 (± 0.72)
Social Functioning, Month 12 (n=194,205,195)	6.4 (± 0.669)	7.7 (± 0.65)	8 (± 0.667)
Vitality, Month 12 (n=194,203,195)	7 (± 0.651)	9.2 (± 0.636)	9.7 (± 0.649)
Bodily Pain, Month 24 (n=192,207,197)	3.2 (± 0.722)	3.3 (± 0.696)	4.1 (± 0.713)
General Health, Month 24 (n=193,207,197)	5.1 (± 0.641)	7.2 (± 0.619)	6.8 (± 0.635)
Mental Health, Month 24 (n=193,203,195)	3.2 (± 0.71)	4.6 (± 0.692)	4 (± 0.706)
Physical Functioning, Month 24 (n=193,207,197)	4.1 (± 0.685)	5.7 (± 0.662)	5.5 (± 0.679)
Role Emotional, Month 24 (n=192,206,196)	4.7 (± 0.793)	6 (± 0.766)	5.9 (± 0.785)
Role-Physical, Month 24 (n=193,207,195)	7.4 (± 0.74)	9.4 (± 0.715)	10.7 (± 0.737)
Social Functioning, Month 24 (n=193, 207,197)	5.9 (± 0.722)	7.4 (± 0.697)	6.3 (± 0.715)
Vitality, Month 24 (n=193,203,196)	6.2 (± 0.7)	7.9 (± 0.682)	8 (± 0.695)
Bodily Pain, Month 36 (n=191,207,196)	2.3 (± 0.739)	4.2 (± 0.71)	3 (± 0.73)
General Health, Month 36 (n=193,207,197)	4.1 (± 0.681)	6.6 (± 0.657)	5.8 (± 0.674)
Mental Health, Month 36 (n=191,204,195)	1.8 (± 0.754)	4.1 (± 0.729)	3.4 (± 0.746)
Physical Functioning, Month 36 (n=192,206,197)	4.4 (± 0.692)	5.3 (± 0.668)	5.1 (± 0.684)
Role Emotional, Month 36 (n=192,207,195)	3.3 (± 0.83)	5.6 (± 0.8)	5 (± 0.824)
Role-Physical, Month 36 (n=192,207,195)	6.8 (± 0.754)	9.2 (± 0.727)	8.9 (± 0.749)
Social Functioning, Month 36 (n=192,207,197)	5.1 (± 0.736)	7 (± 0.708)	5.6 (± 0.726)
Vitality, Month 36 (n=191,204,195)	4.9 (± 0.721)	7.3 (± 0.698)	7.3 (± 0.714)

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects Surviving With a Functioning Graft

End point title	Percent of Subjects Surviving With a Functioning Graft
-----------------	--

End point description:

Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter ($\mu\text{mol/L}$) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the subject underwent retransplant. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 24, 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)				
Month 24	90.5 (86.6 to 94.4)	94.7 (91.8 to 97.6)	94.1 (90.9 to 97.2)	
Month 36	88.7 (84.5 to 92.9)	92 (88.5 to 95.6)	92.2 (88.7 to 95.8)	

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of Subjects with Composite Endpoint or Death, Graft Loss or Acute Rejection by Month 36

End point title	Percent of Subjects with Composite Endpoint or Death, Graft Loss or Acute Rejection by Month 36
-----------------	---

End point description:

Graft loss was defined as either functional loss or physical loss (nephrectomy). Functional loss was defined as a sustained level of serum creatinine (SCr) ≥ 6.0 milligrams per deciliter (mg/dL) or 530 micromoles per liter ($\mu\text{mol/L}$) as determined by the central laboratory for ≥ 4 weeks or ≥ 56 consecutive days of dialysis or impairment of renal function to such a degree that the subject underwent retransplant. Acute rejection was defined as central biopsy proven rejection that was either (1) clinically suspected by protocol defined reasons or (2) clinically suspected by other reasons and treated. Death and graft loss were not imputed. The analysis was performed in all randomised and transplanted subjects, intent to treat (ITT) population.

End point type	Secondary
----------------	-----------

End point timeframe:

Randomisation to Month 36

End point values	Cyclosporine	Belatacept LI	Belatacept MI	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	221	226	219	
Units: percentage of subjects				
number (confidence interval 95%)				
Month 12	13.6 (9.1 to 18.1)	19.5 (14.3 to 24.6)	25.1 (19.4 to 30.9)	
Month 24	18.1 (13 to 23.2)	19.9 (14.7 to 25.1)	27.9 (21.9 to 33.8)	
Month 36	19.9 (14.6 to 25.2)	20.8 (15.5 to 26.1)	28.3 (22.3 to 34.3)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Randomisation to study completion (approximately 10 years)

Adverse event reporting additional description:

Study start: March 2005; Study Completion: April 2015.

All randomised and transplanted subjects, intent to treat (ITT) population

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	18.1
--------------------	------

Reporting groups

Reporting group title	Cyclosporine
-----------------------	--------------

Reporting group description:

Cyclosporine (CsA): tablet, oral

1st month target: 150-300 nanogram/meter (ng/m) After 1st month target: 100-250

nanogram/milliliter (ng/mL), daily, 36 months (short term = ST), 100-250 ng/mL, daily, 24 months (long term = LT)

Reporting group title	Belatacept - MI
-----------------------	-----------------

Reporting group description:

Belatacept MI (more intensive): solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 milligrams/kilogram (mg/kg) every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Reporting group title	Belatacept - LI
-----------------------	-----------------

Reporting group description:

Belatacept LI (less intensive): solution, intravenous (IV), 10 milligrams/kilogram (mg/kg): Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every (q) 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)

Serious adverse events	Cyclosporine	Belatacept - MI	Belatacept - LI
Total subjects affected by serious adverse events			
subjects affected / exposed	167 / 215 (77.67%)	164 / 219 (74.89%)	160 / 226 (70.80%)
number of deaths (all causes)	26	19	15
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Colon cancer			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lip squamous cell carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Metastatic uterine cancer			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Metastases to lung			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	2 / 3	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal oncocytoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thyroid cancer			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anogenital warts			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain neoplasm			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Iris neoplasm			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung neoplasm malignant			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Pancreatic neoplasm			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Sarcoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Throat cancer			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adenoma benign			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basosquamous carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Basal cell carcinoma			
subjects affected / exposed	12 / 215 (5.58%)	8 / 219 (3.65%)	9 / 226 (3.98%)
occurrences causally related to treatment / all	19 / 27	15 / 21	9 / 16
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic malignant melanoma			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic adenoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung cancer metastatic			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Post transplant lymphoproliferative disorder			
subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	2 / 2	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin cancer			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acanthoma			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign breast neoplasm			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder adenocarcinoma stage unspecified			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Chronic myeloid leukaemia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cancer			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of lung			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of skin			
subjects affected / exposed	9 / 215 (4.19%)	9 / 219 (4.11%)	8 / 226 (3.54%)
occurrences causally related to treatment / all	19 / 22	15 / 21	6 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thymic cancer metastatic			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastatic squamous cell carcinoma			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Oesophageal carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Squamous cell carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
B-cell lymphoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervix carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemangioma of liver			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant pleural effusion			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Keratoacanthoma			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parathyroid tumour benign			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder papilloma			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bowen's disease			
subjects affected / exposed	2 / 215 (0.93%)	3 / 219 (1.37%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	4 / 4	5 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cell carcinoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal neoplasm			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Femoral artery occlusion			

subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematoma			
subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	4 / 215 (1.86%)	3 / 219 (1.37%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	3 / 4	0 / 3	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infarction			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial stenosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphocele			
subjects affected / exposed	8 / 215 (3.72%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 8	1 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral vascular disorder			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial thrombosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Embolism venous			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic venous thrombosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral ischaemia			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery dissection			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery stenosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular compression			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive emergency			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phlebitis superficial			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock haemorrhagic			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Capillary leak syndrome			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral artery thrombosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral arterial occlusive disease			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis superficial			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arterial occlusive disease			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	4 / 215 (1.86%)	5 / 219 (2.28%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 4	1 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombophlebitis			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic stenosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Extremity necrosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Hyperthermia			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumatosis			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulcer			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Accidental death			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hernia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 2	2 / 2
deaths causally related to treatment / all	0 / 1	0 / 2	2 / 2
Incarcerated hernia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			

subjects affected / exposed	16 / 215 (7.44%)	13 / 219 (5.94%)	17 / 226 (7.52%)
occurrences causally related to treatment / all	6 / 22	4 / 14	5 / 19
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest discomfort			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthenia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	6 / 215 (2.79%)	6 / 219 (2.74%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 9	0 / 6	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inflammation			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multi-organ failure			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza like illness			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic ulcer			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Transplant rejection			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug hypersensitivity			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal transplant failure			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic allograft nephropathy			
subjects affected / exposed	4 / 215 (1.86%)	4 / 219 (1.83%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	1 / 4	0 / 4	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Acquired hydrocele			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Prostatitis			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vaginal haemorrhage			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Menorrhagia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast calcifications			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Priapism			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine polyp			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Benign prostatic hyperplasia			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometriosis			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pneumonia aspiration			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Pneumothorax			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Asthma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal oedema			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory arrest			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sleep apnoea syndrome			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory distress syndrome			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis chronic			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Lung disorder			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 3	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 4	1 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary hypertension			

subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary oedema			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory distress			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute pulmonary oedema			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 2	0 / 0	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atelectasis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary congestion			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute respiratory failure			

subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Bullous lung disease			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Mania			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute psychosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Completed suicide			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hallucination			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental disorder			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anxiety			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomania			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alcoholism			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Blood glucose fluctuation			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver function test abnormal			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			

subjects affected / exposed	2 / 215 (0.93%)	6 / 219 (2.74%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 4	0 / 7	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatine increased			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	10 / 18	0 / 5	4 / 14
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Blood culture positive			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus test positive			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyomavirus test positive			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	3 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
C-reactive protein increased			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic enzyme increased			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 10	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis test positive			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 10	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ultrasound kidney abnormal			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Weight decreased			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood glucose decreased			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulation test abnormal			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood creatinine increased			
subjects affected / exposed	16 / 215 (7.44%)	5 / 219 (2.28%)	10 / 226 (4.42%)
occurrences causally related to treatment / all	10 / 18	0 / 5	4 / 14
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcus test positive			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Arteriovenous fistula thrombosis			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delayed graft function			

subjects affected / exposed	9 / 215 (4.19%)	2 / 219 (0.91%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	1 / 9	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb injury			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple fractures			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound complication			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal lymphocele			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue injury			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transplant dysfunction			
subjects affected / exposed	7 / 215 (3.26%)	3 / 219 (1.37%)	5 / 226 (2.21%)
occurrences causally related to treatment / all	4 / 7	1 / 3	2 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transplant failure			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric anastomosis complication			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Face injury			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Graft complication			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hip fracture			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Overdose			
subjects affected / exposed	0 / 215 (0.00%)	4 / 219 (1.83%)	7 / 226 (3.10%)
occurrences causally related to treatment / all	0 / 0	1 / 4	4 / 7
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematuria			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Road traffic accident			
subjects affected / exposed	1 / 215 (0.47%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula aneurysm			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest injury			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clavicle fracture			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patella fracture			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of transplanted kidney			

subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Transfusion reaction			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 0	0 / 2	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Craniocerebral injury			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Tendon rupture			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound evisceration			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complications of transplant surgery			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Excoriation			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infusion related reaction			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laceration			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haematoma			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural inflammation			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seroma			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary anastomotic leak			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular graft complication			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula occlusion			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural haemorrhage			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Stenosis of vesicourethral anastomosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carbon monoxide poisoning			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Graft loss			
subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 2	0 / 2	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Humerus fracture			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower limb fracture			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Post procedural complication			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative ileus			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Procedural hypotension			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	9 / 215 (4.19%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	9 / 9	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Congenital, familial and genetic disorders			
Congenital cystic kidney disease			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polycystic liver disease			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Patent ductus arteriosus			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute coronary syndrome			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0

Angina pectoris			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	2 / 215 (0.93%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	1 / 8	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiogenic shock			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve disease			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bradycardia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Left ventricular dysfunction			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular fibrillation			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve disease			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac arrest			
subjects affected / exposed	8 / 215 (3.72%)	3 / 219 (1.37%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 9	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 6	0 / 3	0 / 2
Myocardial ischaemia			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	5 / 215 (2.33%)	4 / 219 (1.83%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	2 / 6	0 / 4	0 / 1
deaths causally related to treatment / all	0 / 2	0 / 1	0 / 0
Coronary artery disease			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pericardial effusion			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulseless electrical activity			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial flutter			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	1 / 215 (0.47%)	6 / 219 (2.74%)	5 / 226 (2.21%)
occurrences causally related to treatment / all	0 / 1	0 / 7	0 / 6
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	3 / 215 (1.40%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 7	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic cardiomyopathy			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal cord compression			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Loss of consciousness			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhage intracranial			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Generalised tonic-clonic seizure			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sciatica			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amnesia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intracranial pressure increased			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Central nervous system lesion			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Carotid artery stenosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	2 / 215 (0.93%)	5 / 219 (2.28%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 2	1 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Migraine			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pineal gland cyst			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	3 / 215 (1.40%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Action tremor			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			

subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myasthenic syndrome			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haematoma			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cervicobrachial syndrome			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mononeuropathy			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Agranulocytosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			

subjects affected / exposed	4 / 215 (1.86%)	4 / 219 (1.83%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 4	2 / 4	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemolytic uraemic syndrome			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anaemia			
subjects affected / exposed	7 / 215 (3.26%)	7 / 219 (3.20%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	1 / 9	2 / 7	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bicytopenia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Febrile neutropenia			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenia			
subjects affected / exposed	1 / 215 (0.47%)	4 / 219 (1.83%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 1	0 / 5	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic cyst			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aplasia pure red cell			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coagulopathy			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphadenopathy			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 215 (0.00%)	4 / 219 (1.83%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	2 / 4	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deafness			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Motion sickness			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Middle ear effusion			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			

Retinal vein occlusion			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papilloedema			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vision blurred			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vitreous haemorrhage			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Ascites			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic gastroparesis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis erosive			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Hernial eventration			

subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Melaena			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	1 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tongue ulceration			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	3 / 215 (1.40%)	3 / 219 (1.37%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 3	1 / 3	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 215 (0.00%)	5 / 219 (2.28%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food poisoning			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	3 / 215 (1.40%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatolithiasis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Volvulus			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal hernia			

subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	8 / 215 (3.72%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 9	1 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain lower			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	9 / 215 (4.19%)	9 / 219 (4.11%)	12 / 226 (5.31%)
occurrences causally related to treatment / all	1 / 10	2 / 12	1 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Incarcerated inguinal hernia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intestinal haemorrhage			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Gastrointestinal disorder			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	4 / 48	10 / 58	2 / 33
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			

subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine perforation			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retroperitoneal haematoma			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric ulcer perforation			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hiatus hernia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus paralytic			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis acute			
subjects affected / exposed	1 / 215 (0.47%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	1 / 5	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombosis mesenteric vessel			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Abdominal compartment syndrome			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastritis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intra-abdominal haemorrhage			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mesenteric arterial occlusion			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Small intestinal obstruction			

subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toothache			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	5 / 215 (2.33%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	2 / 5	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis alcoholic			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic function abnormal			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatosplenomegaly			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangitis			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gallbladder disorder			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stenosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct stone			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cirrhosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Skin ulcer			

subjects affected / exposed	0 / 215 (0.00%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	2 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ingrowing nail			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pruritus			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash generalised			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subcutaneous emphysema			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Actinic keratosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erythema multiforme			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	13 / 215 (6.05%)	6 / 219 (2.74%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	5 / 20	0 / 6	2 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal artery thrombosis			

subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic kidney disease			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis acute			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	2 / 215 (0.93%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal impairment			
subjects affected / exposed	6 / 215 (2.79%)	5 / 219 (2.28%)	7 / 226 (3.10%)
occurrences causally related to treatment / all	6 / 6	1 / 5	1 / 8
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal tubular disorder			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 2	0 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubulointerstitial nephritis			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Azotaemia			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Calculus urinary			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive uropathy			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haematoma			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric stenosis			
subjects affected / exposed	5 / 215 (2.33%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 7	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vesicoureteric reflux			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephritis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal mass			

subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal artery stenosis			
subjects affected / exposed	2 / 215 (0.93%)	3 / 219 (1.37%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 2	0 / 3	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal tubular necrosis			
subjects affected / exposed	4 / 215 (1.86%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	3 / 4	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary incontinence			
subjects affected / exposed	1 / 215 (0.47%)	3 / 219 (1.37%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 1	0 / 3	0 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute prerenal failure			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis membranous			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	4 / 215 (1.86%)	4 / 219 (1.83%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 5	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal vein thrombosis			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal cyst ruptured			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder polyp			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric haemorrhage			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Focal segmental glomerulosclerosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteinuria			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	2 / 4	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal haemorrhage			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal tubular atrophy			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary fistula			

subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract obstruction			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinoma			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anuria			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bladder neck sclerosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephropathy			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary bladder haemorrhage			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteral necrosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hyperparathyroidism			
subjects affected / exposed	5 / 215 (2.33%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 5	0 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperparathyroidism tertiary			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Groin pain			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bursitis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diastasis recti abdominis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neuropathic arthropathy			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acinetobacter infection			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Abdominal sepsis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous graft site infection			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalitis meningococcal			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Furuncle			

subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatitis E			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Histoplasmosis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower respiratory tract infection			
subjects affected / exposed	2 / 215 (0.93%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 2	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periodontitis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	0 / 3	0 / 1
deaths causally related to treatment / all	1 / 1	0 / 0	0 / 0
Subcutaneous abscess			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculosis			
subjects affected / exposed	0 / 215 (0.00%)	3 / 219 (1.37%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	1 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Tuberculosis of intrathoracic lymph nodes			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculosis gastrointestinal			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection enterococcal			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella zoster virus infection			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vulval abscess			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis bacterial			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bone tuberculosis			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	4 / 215 (1.86%)	3 / 219 (1.37%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	3 / 7	2 / 5	3 / 4
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Campylobacter gastroenteritis			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 4	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fungal skin infection			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	7 / 215 (3.26%)	9 / 219 (4.11%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 7	2 / 9	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
H1N1 influenza			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis cryptococcal			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary tuberculosis			

subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	2 / 2	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal urinary tract infection			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tubo-ovarian abscess			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal abscess			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriovenous fistula site infection			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blastomycosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus gastrointestinal infection			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Folliculitis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Localised infection			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymph node tuberculosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral herpes			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	1 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian abscess			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngotonsillitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonas infection			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoas abscess			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	8 / 215 (3.72%)	9 / 219 (4.11%)	6 / 226 (2.65%)
occurrences causally related to treatment / all	3 / 8	3 / 11	2 / 7
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 1
West Nile viral infection			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Abdominal wall abscess			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchitis			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 3	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetic foot infection			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 2	1 / 2	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Labyrinthitis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyomavirus-associated nephropathy			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 1	0 / 2	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Septic shock			
subjects affected / exposed	3 / 215 (1.40%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 3	0 / 2	0 / 2
deaths causally related to treatment / all	1 / 2	0 / 1	0 / 2
Sinusitis			

subjects affected / exposed	0 / 215 (0.00%)	4 / 219 (1.83%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	2 / 4	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Staphylococcal bacteraemia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	5 / 215 (2.33%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	2 / 6	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis infective			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus colitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parvovirus infection			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pharyngitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	2 / 215 (0.93%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 2	1 / 2	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory tract infection			
subjects affected / exposed	3 / 215 (1.40%)	2 / 219 (0.91%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	2 / 3	2 / 2	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tooth abscess			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Varicella			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal abscess			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial infection			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Candida infection			

subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cryptococcosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Cytomegalovirus hepatitis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gangrene			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic cyst infection			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin abscess			

subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising fasciitis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis bacterial			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	17 / 215 (7.91%)	9 / 219 (4.11%)	14 / 226 (6.19%)
occurrences causally related to treatment / all	10 / 22	9 / 12	8 / 17
deaths causally related to treatment / all	1 / 5	0 / 0	0 / 1
Strongyloidiasis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	32 / 215 (14.88%)	21 / 219 (9.59%)	26 / 226 (11.50%)
occurrences causally related to treatment / all	15 / 41	11 / 26	5 / 29
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	3 / 215 (1.40%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	3 / 10	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis			

subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bursitis infective			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus viraemia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal viral infection			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oral candidiasis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parasitic encephalitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia bacterial			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pyelonephritis			
subjects affected / exposed	9 / 215 (4.19%)	8 / 219 (3.65%)	9 / 226 (3.98%)
occurrences causally related to treatment / all	6 / 11	6 / 14	2 / 11
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis viral			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal infection			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal sepsis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound sepsis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
BK virus infection			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	1 / 1	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial diarrhoea			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacterial pyelonephritis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Clostridium difficile infection			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest wall abscess			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus duodenitis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus gastroenteritis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	8 / 215 (3.72%)	16 / 219 (7.31%)	13 / 226 (5.75%)
occurrences causally related to treatment / all	6 / 12	12 / 21	10 / 14
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 0
Cytomegalovirus enteritis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epididymitis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia infection			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis norovirus			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infected skin ulcer			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 0	1 / 2	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orchitis			
subjects affected / exposed	1 / 215 (0.47%)	1 / 219 (0.46%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	2 / 2	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Pertussis			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia legionella			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis syndrome			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sialoadenitis			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tuberculous pleurisy			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	4 / 215 (1.86%)	3 / 219 (1.37%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 4	1 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection			
subjects affected / exposed	2 / 215 (0.93%)	1 / 219 (0.46%)	4 / 226 (1.77%)
occurrences causally related to treatment / all	0 / 2	0 / 1	1 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypocalcaemia			
subjects affected / exposed	2 / 215 (0.93%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			

subjects affected / exposed	0 / 215 (0.00%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	5 / 215 (2.33%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	2 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malnutrition			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolic acidosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acidosis			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 215 (0.00%)	1 / 219 (0.46%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypomagnesaemia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dehydration			
subjects affected / exposed	6 / 215 (2.79%)	5 / 219 (2.28%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	1 / 6	1 / 5	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fluid overload			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus inadequate control			
subjects affected / exposed	1 / 215 (0.47%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gout			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	3 / 215 (1.40%)	1 / 219 (0.46%)	2 / 226 (0.88%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diabetes mellitus			
subjects affected / exposed	4 / 215 (1.86%)	2 / 219 (0.91%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	4 / 5	0 / 2	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Diabetic ketoacidosis			

subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	3 / 226 (1.33%)
occurrences causally related to treatment / all	0 / 1	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Electrolyte imbalance			
subjects affected / exposed	0 / 215 (0.00%)	0 / 219 (0.00%)	1 / 226 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypercalcaemia			
subjects affected / exposed	1 / 215 (0.47%)	0 / 219 (0.00%)	0 / 226 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Cyclosporine	Belatacept - MI	Belatacept - LI
Total subjects affected by non-serious adverse events			
subjects affected / exposed	213 / 215 (99.07%)	216 / 219 (98.63%)	222 / 226 (98.23%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Skin papilloma			
subjects affected / exposed	15 / 215 (6.98%)	14 / 219 (6.39%)	9 / 226 (3.98%)
occurrences (all)	32	23	19
Vascular disorders			
Haematoma			
subjects affected / exposed	16 / 215 (7.44%)	12 / 219 (5.48%)	9 / 226 (3.98%)
occurrences (all)	29	20	22
Hypertension			
subjects affected / exposed	82 / 215 (38.14%)	70 / 219 (31.96%)	87 / 226 (38.50%)
occurrences (all)	186	174	197
Hypotension			
subjects affected / exposed	31 / 215 (14.42%)	45 / 219 (20.55%)	36 / 226 (15.93%)
occurrences (all)	51	72	57
General disorders and administration site conditions			
Oedema			

subjects affected / exposed	25 / 215 (11.63%)	13 / 219 (5.94%)	11 / 226 (4.87%)
occurrences (all)	53	23	22
Chills			
subjects affected / exposed	10 / 215 (4.65%)	9 / 219 (4.11%)	15 / 226 (6.64%)
occurrences (all)	12	13	18
Oedema peripheral			
subjects affected / exposed	87 / 215 (40.47%)	64 / 219 (29.22%)	70 / 226 (30.97%)
occurrences (all)	283	171	197
Pain			
subjects affected / exposed	14 / 215 (6.51%)	20 / 219 (9.13%)	14 / 226 (6.19%)
occurrences (all)	24	35	21
Pyrexia			
subjects affected / exposed	56 / 215 (26.05%)	61 / 219 (27.85%)	68 / 226 (30.09%)
occurrences (all)	92	153	113
Asthenia			
subjects affected / exposed	21 / 215 (9.77%)	16 / 219 (7.31%)	27 / 226 (11.95%)
occurrences (all)	38	24	39
Chest pain			
subjects affected / exposed	21 / 215 (9.77%)	22 / 219 (10.05%)	17 / 226 (7.52%)
occurrences (all)	40	39	32
Fatigue			
subjects affected / exposed	32 / 215 (14.88%)	22 / 219 (10.05%)	27 / 226 (11.95%)
occurrences (all)	63	50	65
Peripheral swelling			
subjects affected / exposed	9 / 215 (4.19%)	12 / 219 (5.48%)	8 / 226 (3.54%)
occurrences (all)	21	31	16
Immune system disorders			
Chronic allograft nephropathy			
subjects affected / exposed	21 / 215 (9.77%)	5 / 219 (2.28%)	4 / 226 (1.77%)
occurrences (all)	23	8	4
Reproductive system and breast disorders			
Erectile dysfunction			
subjects affected / exposed	14 / 215 (6.51%)	10 / 219 (4.57%)	8 / 226 (3.54%)
occurrences (all)	26	12	21
Respiratory, thoracic and mediastinal disorders			

Productive cough subjects affected / exposed occurrences (all)	9 / 215 (4.19%) 17	10 / 219 (4.57%) 20	15 / 226 (6.64%) 35
Cough subjects affected / exposed occurrences (all)	57 / 215 (26.51%) 174	69 / 219 (31.51%) 226	81 / 226 (35.84%) 213
Dyspnoea subjects affected / exposed occurrences (all)	36 / 215 (16.74%) 63	16 / 219 (7.31%) 37	18 / 226 (7.96%) 32
Rhinorrhoea subjects affected / exposed occurrences (all)	10 / 215 (4.65%) 26	11 / 219 (5.02%) 25	13 / 226 (5.75%) 30
Oropharyngeal pain subjects affected / exposed occurrences (all)	14 / 215 (6.51%) 26	19 / 219 (8.68%) 33	28 / 226 (12.39%) 45
Nasal congestion subjects affected / exposed occurrences (all)	4 / 215 (1.86%) 7	12 / 219 (5.48%) 22	11 / 226 (4.87%) 24
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	18 / 215 (8.37%) 23	26 / 219 (11.87%) 38	17 / 226 (7.52%) 26
Insomnia subjects affected / exposed occurrences (all)	38 / 215 (17.67%) 73	42 / 219 (19.18%) 112	39 / 226 (17.26%) 71
Anxiety subjects affected / exposed occurrences (all)	27 / 215 (12.56%) 38	27 / 219 (12.33%) 45	26 / 226 (11.50%) 53
Investigations			
Weight increased subjects affected / exposed occurrences (all)	24 / 215 (11.16%) 41	27 / 219 (12.33%) 51	24 / 226 (10.62%) 43
C-reactive protein increased subjects affected / exposed occurrences (all)	11 / 215 (5.12%) 23	12 / 219 (5.48%) 52	10 / 226 (4.42%) 25
Weight decreased			

subjects affected / exposed	8 / 215 (3.72%)	27 / 219 (12.33%)	22 / 226 (9.73%)
occurrences (all)	13	62	43
Blood creatinine increased			
subjects affected / exposed	53 / 215 (24.65%)	26 / 219 (11.87%)	25 / 226 (11.06%)
occurrences (all)	129	60	53
Injury, poisoning and procedural complications			
Delayed graft function			
subjects affected / exposed	28 / 215 (13.02%)	22 / 219 (10.05%)	26 / 226 (11.50%)
occurrences (all)	49	43	47
Transplant dysfunction			
subjects affected / exposed	12 / 215 (5.58%)	5 / 219 (2.28%)	7 / 226 (3.10%)
occurrences (all)	22	7	10
Contusion			
subjects affected / exposed	8 / 215 (3.72%)	11 / 219 (5.02%)	8 / 226 (3.54%)
occurrences (all)	14	35	21
Fall			
subjects affected / exposed	16 / 215 (7.44%)	10 / 219 (4.57%)	11 / 226 (4.87%)
occurrences (all)	25	19	18
Incision site pain			
subjects affected / exposed	38 / 215 (17.67%)	33 / 219 (15.07%)	30 / 226 (13.27%)
occurrences (all)	71	68	57
Complications of transplanted kidney			
subjects affected / exposed	13 / 215 (6.05%)	7 / 219 (3.20%)	10 / 226 (4.42%)
occurrences (all)	19	11	19
Complications of transplant surgery			
subjects affected / exposed	9 / 215 (4.19%)	11 / 219 (5.02%)	7 / 226 (3.10%)
occurrences (all)	12	17	12
Procedural pain			
subjects affected / exposed	40 / 215 (18.60%)	41 / 219 (18.72%)	40 / 226 (17.70%)
occurrences (all)	85	79	91
Ligament sprain			
subjects affected / exposed	7 / 215 (3.26%)	12 / 219 (5.48%)	4 / 226 (1.77%)
occurrences (all)	12	20	7
Toxicity to various agents			

subjects affected / exposed occurrences (all)	27 / 215 (12.56%) 37	2 / 219 (0.91%) 2	3 / 226 (1.33%) 4
Cardiac disorders			
Bradycardia			
subjects affected / exposed	13 / 215 (6.05%)	8 / 219 (3.65%)	9 / 226 (3.98%)
occurrences (all)	21	10	14
Tachycardia			
subjects affected / exposed	23 / 215 (10.70%)	19 / 219 (8.68%)	12 / 226 (5.31%)
occurrences (all)	43	31	18
Nervous system disorders			
Headache			
subjects affected / exposed	46 / 215 (21.40%)	65 / 219 (29.68%)	75 / 226 (33.19%)
occurrences (all)	114	151	177
Dizziness			
subjects affected / exposed	32 / 215 (14.88%)	24 / 219 (10.96%)	25 / 226 (11.06%)
occurrences (all)	74	40	57
Hypoaesthesia			
subjects affected / exposed	7 / 215 (3.26%)	12 / 219 (5.48%)	19 / 226 (8.41%)
occurrences (all)	10	22	31
Paraesthesia			
subjects affected / exposed	19 / 215 (8.84%)	7 / 219 (3.20%)	18 / 226 (7.96%)
occurrences (all)	33	12	35
Tremor			
subjects affected / exposed	43 / 215 (20.00%)	19 / 219 (8.68%)	19 / 226 (8.41%)
occurrences (all)	103	28	37
Blood and lymphatic system disorders			
Leukopenia			
subjects affected / exposed	37 / 215 (17.21%)	40 / 219 (18.26%)	48 / 226 (21.24%)
occurrences (all)	84	100	101
Polycythaemia			
subjects affected / exposed	11 / 215 (5.12%)	14 / 219 (6.39%)	17 / 226 (7.52%)
occurrences (all)	16	38	46
Anaemia			
subjects affected / exposed	86 / 215 (40.00%)	85 / 219 (38.81%)	92 / 226 (40.71%)
occurrences (all)	217	181	253
Leukocytosis			

subjects affected / exposed	9 / 215 (4.19%)	10 / 219 (4.57%)	16 / 226 (7.08%)
occurrences (all)	15	21	32
Neutropenia			
subjects affected / exposed	10 / 215 (4.65%)	9 / 219 (4.11%)	14 / 226 (6.19%)
occurrences (all)	20	16	26
Thrombocytopenia			
subjects affected / exposed	20 / 215 (9.30%)	16 / 219 (7.31%)	9 / 226 (3.98%)
occurrences (all)	33	25	20
Ear and labyrinth disorders			
Tinnitus			
subjects affected / exposed	7 / 215 (3.26%)	5 / 219 (2.28%)	12 / 226 (5.31%)
occurrences (all)	11	7	17
Ear pain			
subjects affected / exposed	3 / 215 (1.40%)	5 / 219 (2.28%)	13 / 226 (5.75%)
occurrences (all)	4	9	27
Eye disorders			
Cataract			
subjects affected / exposed	11 / 215 (5.12%)	10 / 219 (4.57%)	7 / 226 (3.10%)
occurrences (all)	23	13	12
Gastrointestinal disorders			
Gastroesophageal reflux disease			
subjects affected / exposed	13 / 215 (6.05%)	11 / 219 (5.02%)	19 / 226 (8.41%)
occurrences (all)	18	18	45
Nausea			
subjects affected / exposed	70 / 215 (32.56%)	59 / 219 (26.94%)	62 / 226 (27.43%)
occurrences (all)	187	128	150
Vomiting			
subjects affected / exposed	46 / 215 (21.40%)	45 / 219 (20.55%)	55 / 226 (24.34%)
occurrences (all)	96	93	102
Flatulence			
subjects affected / exposed	11 / 215 (5.12%)	9 / 219 (4.11%)	16 / 226 (7.08%)
occurrences (all)	14	14	26
Gingival hyperplasia			
subjects affected / exposed	18 / 215 (8.37%)	2 / 219 (0.91%)	0 / 226 (0.00%)
occurrences (all)	31	4	0
Abdominal discomfort			

subjects affected / exposed	11 / 215 (5.12%)	8 / 219 (3.65%)	7 / 226 (3.10%)
occurrences (all)	19	14	15
Abdominal pain upper			
subjects affected / exposed	24 / 215 (11.16%)	19 / 219 (8.68%)	22 / 226 (9.73%)
occurrences (all)	37	49	36
Constipation			
subjects affected / exposed	68 / 215 (31.63%)	65 / 219 (29.68%)	83 / 226 (36.73%)
occurrences (all)	147	137	162
Dyspepsia			
subjects affected / exposed	26 / 215 (12.09%)	20 / 219 (9.13%)	35 / 226 (15.49%)
occurrences (all)	41	32	63
Abdominal pain			
subjects affected / exposed	40 / 215 (18.60%)	47 / 219 (21.46%)	48 / 226 (21.24%)
occurrences (all)	88	100	89
Abdominal pain lower			
subjects affected / exposed	6 / 215 (2.79%)	13 / 219 (5.94%)	13 / 226 (5.75%)
occurrences (all)	17	27	17
Diarrhoea			
subjects affected / exposed	92 / 215 (42.79%)	118 / 219 (53.88%)	115 / 226 (50.88%)
occurrences (all)	228	374	384
Haemorrhoids			
subjects affected / exposed	15 / 215 (6.98%)	14 / 219 (6.39%)	19 / 226 (8.41%)
occurrences (all)	21	22	88
Mouth ulceration			
subjects affected / exposed	3 / 215 (1.40%)	11 / 219 (5.02%)	7 / 226 (3.10%)
occurrences (all)	5	33	18
Abdominal distension			
subjects affected / exposed	17 / 215 (7.91%)	16 / 219 (7.31%)	15 / 226 (6.64%)
occurrences (all)	27	26	29
Aphthous ulcer			
subjects affected / exposed	5 / 215 (2.33%)	13 / 219 (5.94%)	16 / 226 (7.08%)
occurrences (all)	15	35	44
Gastritis			
subjects affected / exposed	12 / 215 (5.58%)	11 / 219 (5.02%)	14 / 226 (6.19%)
occurrences (all)	23	18	26
Skin and subcutaneous tissue disorders			

Skin lesion			
subjects affected / exposed	15 / 215 (6.98%)	24 / 219 (10.96%)	22 / 226 (9.73%)
occurrences (all)	31	57	45
Acne			
subjects affected / exposed	31 / 215 (14.42%)	23 / 219 (10.50%)	22 / 226 (9.73%)
occurrences (all)	65	45	57
Alopecia			
subjects affected / exposed	8 / 215 (3.72%)	16 / 219 (7.31%)	19 / 226 (8.41%)
occurrences (all)	10	29	45
Night sweats			
subjects affected / exposed	6 / 215 (2.79%)	12 / 219 (5.48%)	11 / 226 (4.87%)
occurrences (all)	10	18	17
Pruritus			
subjects affected / exposed	17 / 215 (7.91%)	15 / 219 (6.85%)	17 / 226 (7.52%)
occurrences (all)	21	30	21
Hypertrichosis			
subjects affected / exposed	11 / 215 (5.12%)	4 / 219 (1.83%)	0 / 226 (0.00%)
occurrences (all)	17	5	0
Hyperhidrosis			
subjects affected / exposed	6 / 215 (2.79%)	9 / 219 (4.11%)	12 / 226 (5.31%)
occurrences (all)	8	11	18
Rash			
subjects affected / exposed	15 / 215 (6.98%)	20 / 219 (9.13%)	22 / 226 (9.73%)
occurrences (all)	32	34	38
Renal and urinary disorders			
Dysuria			
subjects affected / exposed	34 / 215 (15.81%)	34 / 219 (15.53%)	26 / 226 (11.50%)
occurrences (all)	57	59	42
Haematuria			
subjects affected / exposed	41 / 215 (19.07%)	33 / 219 (15.07%)	39 / 226 (17.26%)
occurrences (all)	101	69	66
Leukocyturia			
subjects affected / exposed	9 / 215 (4.19%)	6 / 219 (2.74%)	13 / 226 (5.75%)
occurrences (all)	21	25	26
Renal impairment			

subjects affected / exposed	14 / 215 (6.51%)	7 / 219 (3.20%)	10 / 226 (4.42%)
occurrences (all)	22	12	20
Renal tubular necrosis			
subjects affected / exposed	19 / 215 (8.84%)	20 / 219 (9.13%)	17 / 226 (7.52%)
occurrences (all)	29	27	32
Proteinuria			
subjects affected / exposed	30 / 215 (13.95%)	30 / 219 (13.70%)	41 / 226 (18.14%)
occurrences (all)	57	98	95
Musculoskeletal and connective tissue disorders			
Pain in extremity			
subjects affected / exposed	33 / 215 (15.35%)	36 / 219 (16.44%)	40 / 226 (17.70%)
occurrences (all)	96	106	79
Osteoarthritis			
subjects affected / exposed	7 / 215 (3.26%)	14 / 219 (6.39%)	9 / 226 (3.98%)
occurrences (all)	9	23	17
Osteoporosis			
subjects affected / exposed	6 / 215 (2.79%)	8 / 219 (3.65%)	15 / 226 (6.64%)
occurrences (all)	6	44	18
Arthralgia			
subjects affected / exposed	37 / 215 (17.21%)	51 / 219 (23.29%)	54 / 226 (23.89%)
occurrences (all)	99	130	116
Myalgia			
subjects affected / exposed	17 / 215 (7.91%)	19 / 219 (8.68%)	27 / 226 (11.95%)
occurrences (all)	29	27	55
Osteopenia			
subjects affected / exposed	13 / 215 (6.05%)	12 / 219 (5.48%)	14 / 226 (6.19%)
occurrences (all)	21	13	18
Musculoskeletal pain			
subjects affected / exposed	12 / 215 (5.58%)	17 / 219 (7.76%)	17 / 226 (7.52%)
occurrences (all)	27	30	30
Back pain			
subjects affected / exposed	38 / 215 (17.67%)	47 / 219 (21.46%)	44 / 226 (19.47%)
occurrences (all)	63	99	75
Muscular weakness			

subjects affected / exposed	14 / 215 (6.51%)	4 / 219 (1.83%)	8 / 226 (3.54%)
occurrences (all)	21	6	10
Muscle spasms			
subjects affected / exposed	17 / 215 (7.91%)	16 / 219 (7.31%)	11 / 226 (4.87%)
occurrences (all)	36	27	23
Infections and infestations			
Fungal skin infection			
subjects affected / exposed	9 / 215 (4.19%)	10 / 219 (4.57%)	16 / 226 (7.08%)
occurrences (all)	20	23	29
Gastroenteritis			
subjects affected / exposed	20 / 215 (9.30%)	25 / 219 (11.42%)	19 / 226 (8.41%)
occurrences (all)	24	39	34
Conjunctivitis			
subjects affected / exposed	9 / 215 (4.19%)	12 / 219 (5.48%)	11 / 226 (4.87%)
occurrences (all)	17	22	18
Oral herpes			
subjects affected / exposed	12 / 215 (5.58%)	16 / 219 (7.31%)	22 / 226 (9.73%)
occurrences (all)	22	40	51
Onychomycosis			
subjects affected / exposed	10 / 215 (4.65%)	15 / 219 (6.85%)	16 / 226 (7.08%)
occurrences (all)	33	29	36
Bronchitis			
subjects affected / exposed	21 / 215 (9.77%)	22 / 219 (10.05%)	29 / 226 (12.83%)
occurrences (all)	47	51	69
Herpes zoster			
subjects affected / exposed	19 / 215 (8.84%)	20 / 219 (9.13%)	14 / 226 (6.19%)
occurrences (all)	34	40	26
Sinusitis			
subjects affected / exposed	18 / 215 (8.37%)	17 / 219 (7.76%)	24 / 226 (10.62%)
occurrences (all)	37	30	56
Tinea versicolour			
subjects affected / exposed	15 / 215 (6.98%)	6 / 219 (2.74%)	11 / 226 (4.87%)
occurrences (all)	24	12	26
Upper respiratory tract infection			
subjects affected / exposed	52 / 215 (24.19%)	60 / 219 (27.40%)	56 / 226 (24.78%)
occurrences (all)	144	184	163

Pharyngitis			
subjects affected / exposed	18 / 215 (8.37%)	17 / 219 (7.76%)	22 / 226 (9.73%)
occurrences (all)	43	53	52
Candida infection			
subjects affected / exposed	4 / 215 (1.86%)	11 / 219 (5.02%)	8 / 226 (3.54%)
occurrences (all)	8	19	16
Influenza			
subjects affected / exposed	27 / 215 (12.56%)	37 / 219 (16.89%)	40 / 226 (17.70%)
occurrences (all)	99	104	113
Nasopharyngitis			
subjects affected / exposed	49 / 215 (22.79%)	49 / 219 (22.37%)	39 / 226 (17.26%)
occurrences (all)	149	117	130
Urinary tract infection			
subjects affected / exposed	77 / 215 (35.81%)	71 / 219 (32.42%)	91 / 226 (40.27%)
occurrences (all)	271	432	378
Pneumonia			
subjects affected / exposed	8 / 215 (3.72%)	11 / 219 (5.02%)	14 / 226 (6.19%)
occurrences (all)	11	21	20
Oral candidiasis			
subjects affected / exposed	14 / 215 (6.51%)	19 / 219 (8.68%)	11 / 226 (4.87%)
occurrences (all)	27	57	23
BK virus infection			
subjects affected / exposed	11 / 215 (5.12%)	13 / 219 (5.94%)	9 / 226 (3.98%)
occurrences (all)	15	22	14
Cytomegalovirus infection			
subjects affected / exposed	19 / 215 (8.84%)	10 / 219 (4.57%)	13 / 226 (5.75%)
occurrences (all)	38	32	38
Metabolism and nutrition disorders			
Hyperkalaemia			
subjects affected / exposed	44 / 215 (20.47%)	18 / 219 (8.22%)	41 / 226 (18.14%)
occurrences (all)	102	31	64
Hypertriglyceridaemia			
subjects affected / exposed	11 / 215 (5.12%)	15 / 219 (6.85%)	6 / 226 (2.65%)
occurrences (all)	18	67	9
Hypoglycaemia			

subjects affected / exposed	18 / 215 (8.37%)	13 / 219 (5.94%)	15 / 226 (6.64%)
occurrences (all)	39	19	26
Hypocalcaemia			
subjects affected / exposed	25 / 215 (11.63%)	17 / 219 (7.76%)	27 / 226 (11.95%)
occurrences (all)	59	35	45
Hypokalaemia			
subjects affected / exposed	28 / 215 (13.02%)	48 / 219 (21.92%)	49 / 226 (21.68%)
occurrences (all)	73	108	107
Hyponatraemia			
subjects affected / exposed	12 / 215 (5.58%)	6 / 219 (2.74%)	7 / 226 (3.10%)
occurrences (all)	26	8	12
Metabolic acidosis			
subjects affected / exposed	19 / 215 (8.84%)	13 / 219 (5.94%)	8 / 226 (3.54%)
occurrences (all)	28	17	13
Vitamin D deficiency			
subjects affected / exposed	9 / 215 (4.19%)	17 / 219 (7.76%)	21 / 226 (9.29%)
occurrences (all)	16	27	30
Hyperglycaemia			
subjects affected / exposed	42 / 215 (19.53%)	42 / 219 (19.18%)	38 / 226 (16.81%)
occurrences (all)	78	65	72
Hypercholesterolaemia			
subjects affected / exposed	26 / 215 (12.09%)	34 / 219 (15.53%)	31 / 226 (13.72%)
occurrences (all)	53	90	62
Hypomagnesaemia			
subjects affected / exposed	24 / 215 (11.16%)	18 / 219 (8.22%)	17 / 226 (7.52%)
occurrences (all)	53	29	32
Dehydration			
subjects affected / exposed	15 / 215 (6.98%)	6 / 219 (2.74%)	11 / 226 (4.87%)
occurrences (all)	20	8	18
Hypophosphataemia			
subjects affected / exposed	33 / 215 (15.35%)	36 / 219 (16.44%)	51 / 226 (22.57%)
occurrences (all)	75	80	103
Decreased appetite			
subjects affected / exposed	13 / 215 (6.05%)	13 / 219 (5.94%)	23 / 226 (10.18%)
occurrences (all)	26	25	46
Dyslipidaemia			

subjects affected / exposed	70 / 215 (32.56%)	62 / 219 (28.31%)	59 / 226 (26.11%)
occurrences (all)	276	173	186
Gout			
subjects affected / exposed	11 / 215 (5.12%)	2 / 219 (0.91%)	10 / 226 (4.42%)
occurrences (all)	19	4	25
Diabetes mellitus			
subjects affected / exposed	15 / 215 (6.98%)	23 / 219 (10.50%)	19 / 226 (8.41%)
occurrences (all)	30	72	28
Hypercalcaemia			
subjects affected / exposed	13 / 215 (6.05%)	16 / 219 (7.31%)	16 / 226 (7.08%)
occurrences (all)	29	34	53
Iron deficiency			
subjects affected / exposed	8 / 215 (3.72%)	11 / 219 (5.02%)	11 / 226 (4.87%)
occurrences (all)	17	27	32
Hyperlipidaemia			
subjects affected / exposed	20 / 215 (9.30%)	19 / 219 (8.68%)	19 / 226 (8.41%)
occurrences (all)	27	35	27
Hyperuricaemia			
subjects affected / exposed	36 / 215 (16.74%)	8 / 219 (3.65%)	11 / 226 (4.87%)
occurrences (all)	87	15	22

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 March 2007	<ul style="list-style-type: none">• Changed statistical methodology,• Changed pharmacokinetic sampling regimen,• Changed exclusion criterion for tuberculosis infection,• Clarified Cytomegalovirus prophylaxis regimen,• Added ATG-Fresenius-S to list of permitted polyclonal anti lymphocyte preparations,• Extended the baseline mammogram window,• Clarified performance of baseline biopsy,• Clarified hepatitis B and C and HIV exclusion criterion.• Changed administration of basiliximab.
21 December 2007	<ul style="list-style-type: none">• Addition of the 250 mg/vial of Belatacept to the list of investigational products,• Addition of long-term extension phase, extending the study two years,• Additional information on contraception use for women of child bearing potential with regard to mycophenolate mofetil (MMF).
18 October 2010	<ul style="list-style-type: none">• Continuance of long-term extension,• Addition of immunogenicity assessments after discontinuation,• Discontinuation of Quality of Life Short Form-36 (SF-36) after year 5, month 60.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported